L7 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2002 ACS

AB A review with 232 refs. Serotonin (5-hydroxytryptamine) is an important biogenic amine that fulfills the role of neurotransmitter and neuromodulator. It has been a focus of interest during the last decade. Its diversity of pharmacol. actions is related to a wide variety of receptors and effector mechanisms. Seven serotonin receptor families have been identified thus far. They are genetically different transmembrane proteins composed of several hundred amino acids. The majority of these are G-protein-coupled, except the 5-HT3 receptors, which are directly ligand gated to fast ion channels. Serotonin is widely distributed in the body within the central and peripheral nervous systems, smooth muscles, and platelets, in particular. Consequently, its effects manifest mainly in these organs and influence a wide variety of neural, vascular, smooth muscle, and platelet functions. (Melatonin, a physiol. active metabolite of serotonin, is also instrumental in affecting many neural and hormonal functions.). Several selective agonists and particularly many selective antagonists have been developed for serotonin, which helped the serotonin receptor subtype classification. Some of these drugs are also used therapeutically in the treatment of migraine (eg, sumatriptan, which is a 5-HT1 receptor agonist), vascular disorders (5-HT2 antagonists), and nausea and vomiting (5-HT3 antagonists, eg, dolasetron, granisetron, ondansetron, and tropisetron), and have been investigated in gastrointestinal motility disorders (5-HT4 antagonists) and behavioral psychopathologies (5-HT1 agonists and 5-HT2-4 antagonists). Serotonin reuptake inhibitors are of particular clin. importance in the treatment of psychol. illnesses. Future use of these drugs is also envisioned in the treatment of certain types of **pain** syndromes. Awareness of the serotonergic drugs and the recognition of possible drug interactions among drugs that influence serotonergic mechanisms in humans are becoming increasingly important in the practice of anesthesiol.

AN 1997:365215 CAPLUS
DN 127:28509

TI Pharmacology of serotonin as related to anesthesia

AU Gyermek, Laszlo
CS Department of Anesthesiology, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance, CA, USA

SO J. Clin. Anesth. (1996), 8(5), 402-425
CODEN: JCLBE7; ISSN: 0952-8180
PB Elsevier
DT Journal; General Review
LA English

9980965.trn10/01/2003

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:41:55 ON 13 MAY 2002

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 16:43:45 ON 13 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 12 MAY 2002 HIGHEST RN 414856-11-4
DICTIONARY FILE UPDATES: 12 MAY 2002 HIGHEST RN 414856-11-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 9980965.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> sl1 ful
SL1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l1 ful

```
FULL SEARCH INITIATED 16:44:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  63956 TO ITERATE

100.0% PROCESSED   63956 ITERATIONS                          188 ANSWERS
SEARCH TIME: 00.00.01

L2          188 SEA SSS FUL L1

=> file uspatall
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   140.28     140.91

FILE 'USPATFULL' ENTERED AT 16:44:16 ON 13 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:44:16 ON 13 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2
L3            6 L2

=> d abs bib hitstr 1-6

L3   ANSWER 1 OF 6  USPATFULL
AB     This invention relates to certain novel compounds and derivatives
       thereof, their synthesis, and their use as selective alpha-1C adrenergic
       receptor antagonists. One application of these compounds is in the
       treatment of benign prostatic hypertrophy. These compounds are selective
       in their ability to relax smooth muscle tissue enriched in the alpha1C
       receptor subtype without at the same time inducing orthostatic
       hypotension. One such tissue is found surrounding the urethral lining.
       Therefore, one utility of the instant compounds is to provide acute
       relief to males suffering from benign prostatic hyperplasia, by
       permitting less hindered urine flow. Another utility of the instant
       compounds is provided by combination with a human 5-alpha reductase
       inhibitory compound, such that both acute and chronic relief from the
       effects of benign prostatic hyperplasia are achieved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     1998:61669  USPATFULL
TI     Alpha IC adrenergic receptor antagonists
IN     Huff, Joel R., Gwynedd Valley, PA, United States
       Lee, Hee-Yoon, Yusung-Gu, Korea, Republic of
       Nerenberg, Jennie B., Maple Glen, PA, United States
       Thompson, Wayne J., Lansdale, PA, United States
       Bell, Ian M., Harleysville, PA, United States
PA     Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI     US 5760054            19980602
       WO 9528397 19951026
AI     US 1996-722001        19961001 (8)
       WO 1995-US4590        19950413
                             19961001  PCT 371 date
                             19961001  PCT 102(e) date
RLI    Continuation-in-part of Ser. No. US 1994-229276, filed on 13 Apr 1994,
       now abandoned
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Rotman, Alan L.
LREP   Winokur, Melvin
```

CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **173842-22-3P**
(prepn. of benzisothiazolones and analogs as .alpha.1C-adrenergic antagonists)
RN 173842-22-3 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[4-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



IT **136080-34-7**
(prepn. of benzisothiazolones and analogs as .alpha.1C-adrenergic antagonists)
RN 136080-34-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 6 USPATFULL
AB Spirocycles of general structural formula: ##STR1## are Class III antiarrhythmic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:45012 USPATFULL
TI Nitrogen-containing spirocycles
IN Baldwin, John J., Gwyned Valley, PA, United States
Claremon, David A., Audubon, PA, United States
Elliott, Jason M., Blue Bell, PA, United States
Ponticello, Gerald S., Lansdale, PA, United States
Remy, David C., North Wales, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5633247 19970527
AI US 1995-498525 19950705 (8)
RLI Continuation of Ser. No. US 1992-998321, filed on 30 Dec 1992, now abandoned which is a division of Ser. No. US 1991-709686, filed on 3 Jun 1991, now patented, Pat. No. US 5206240 which is a continuation-in-part of Ser. No. US 1990-612091, filed on 16 Nov 1990, now abandoned which is

a continuation-in-part of Ser. No. US 1989-447950, filed on 8 Dec 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Covington, Raymond
LREP Bigley, Frank P., Daniel, Mark R.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **136081-76-0P**
(prepn. of, as antiarrhythmic and cardiotonic)
RN 136081-76-0 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **136074-77-6P 136074-78-7P 136074-79-8P 136074-80-1P 136074-81-2P**
(prepn. of, as class III antiarrhythmic and cardiotonic)
RN 136074-77-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-78-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-79-8 USPATFULL

CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]- (9CI) (CA INDEX NAME)



RN 136074-80-1 USPATFULL
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 136074-81-2 USPATFULL
CN Methanesulfonamide, N-[4-[2-[3,4-dihydro-7-[(methylsulfonyl)amino]-1-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



IT **136080-33-6P 136080-34-7P 136080-35-8P 136080-36-9P 136112-40-8P**
(prepn. of, as intermediates for antiarrhythmic and cardiotonic)
RN 136080-33-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid, 3,4-dihydro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 136080-34-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 136080-35-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 136080-36-9 USPATFULL
CN Methanesulfonamide, N-(3,4-dihydro-1-oxospiro[naphthalene-2(1H),4'-piperidin]-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 136112-40-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 6 USPATFULL
AB Compounds of the general structural formula: ##STR1## or a pharmaceutically acceptable salt, hydrate or crystal form thereof, wherein;

X is O or CH.sub.2

R.sup.1 is H if R.sup.2 is not H or if R.sup.2 is H then R.sup.1 is ##STR2## R.sup.2 is --H if R.sup.1 is not H or if R.sup.1 is H then R.sup.2 is; ##STR3## and R.sup.3 is ##STR4## are Class HI antiarrhythmic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:71364 USPATFULL
TI Spirocycles
IN Claremon, David A., Maple Glen, PA, United States
Ponticello, Gerald S., Lansdale, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5439914 19950808
AI US 1994-198940 19940218 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Berch, Mark L.
LREP Bigley, Francis P., Daniel, Mark R., DiPrima, Joseph F.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **171797-76-5P 171797-77-6P 171797-78-7P**
171797-79-8P
(intermediate; prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-76-5 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-4(3H)-one, 1'-benzoyl-6-methoxy- (9CI) (CA INDEX NAME)



RN 171797-77-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-4(3H)-one, 6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-78-7 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-6-methoxy-4-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-79-8 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-6-methoxy-4-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]- (9CI) (CA INDEX NAME)



IT **171797-63-0P**
(prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-63-0 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-4-hydroxy-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]- (9CI) (CA INDEX NAME)



IT **171797-64-1P 171797-65-2P 171797-66-3P**
171797-67-4P 171797-68-5P
(prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-64-1 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-4-hydroxy-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-65-2 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 171797-66-3 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-67-4 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171797-68-5 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 4 OF 6 USPATFULL

AB Compounds of formula (I): ##STR1## in which: R.sub.1 and R.sub.2, which may be identical or different, represent a linear or branched (C.sub.1 C.sub.6) alkyl radical, a substituted or unsubstituted phenyl radical, a pyridyl radical or a thienyl radical, or, with the carbon atom to which they are attached, a substituted or unsubstituted (C.sub.4 -C.sub.7) cycloalkyl ring,

R.sub.3 represents

a substituted or unsubstituted phenylsulfonyl radical,

a linear or branched (C.sub.1 -C.sub.6) alkyl radical,

an alkylaminocarbonyl radical,

or a linear or branched (C.sub.1 -C.sub.6) acyl radical,

R.sub.4 represents any one of the radicals:

--CH.dbd.CH--(CH.sub.2).sub.p --CO.sub.2 H or --CH.sub.2 --CH.sub.2 --(CH.sub.2)p--CO.sub.2 H

in which p is equal to 0, 1, 2 or 3, n and m, which may be identical or different, represent 0, 1 or 2,

their isomers, enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid or base.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:67331 USPATFULL
TI Alkenecarboxylic acid compounds
IN Lavielle, Gilbert, La Celle Saint Cloud, France
Hautefaye, Patrick, Servon Brie Comte Robert, France
Laubie, Michel, Vaucresson, France
Verbeuren, Tony, Vernouillet, France
PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)
PI US 5436343 19950725
AI US 1993-62080 19930514 (8)
PRAI FR 1992-5905 19920515
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Jones, Dwayne C.
LREP Hueschen, Gordon W.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **154678-95-2P**
(prepn. and reaction of, in prepn. of aminoalkenecarboxylic acid thromboxane A2 receptor antagonist)
RN 154678-95-2 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidine]-3',5'-dicarbonitrile, 3,4-dihydro-2',6'-dioxo-, ammonium salt (9CI) (CA INDEX NAME)



● NH_3

L3 ANSWER 5 OF 6 USPATFULL
AB Spirocycles of general structural formula: ##STR1## are Class III antiarrhythmic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 93:33493 USPATFULL
TI Nitrogen-containing spirocycles
IN Baldwin, John J., Gwynedd Valley, PA, United States
Elliott, Jason M., Blue Bell, PA, United States
Claremon, David A., Audubon, PA, United States
Ponticello, Gerald S., Lansdale, PA, United States
Remy, David C., North Wales, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206240 19930427
AI US 1991-709686 19910603 (7)
RLI Continuation-in-part of Ser. No. US 1990-612091, filed on 16 Nov 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-447950, filed on 8 Dec 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Brust, Joseph P.; Assistant Examiner: Haley, Jacqueline
LREP Daniel, Mark R., DiPrima, Joseph F.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **136081-76-0P**
(prepn. of, as antiarrhythmic and cardiotonic)
RN 136081-76-0 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **136074-77-6P 136074-78-7P 136074-79-8P**
136074-80-1P 136074-81-2P
(prepn. of, as class III antiarrhythmic and cardiotonic)
RN 136074-77-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-78-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-79-8 USPATFULL
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]- (9CI) (CA INDEX NAME)



RN 136074-80-1 USPATFULL
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 136074-81-2 USPATFULL
CN Methanesulfonamide, N-[4-[2-[3,4-dihydro-7-[(methylsulfonyl)amino]-1-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



IT **136080-33-6P 136080-34-7P 136080-35-8P**
136080-36-9P 136112-40-8P
(prepn. of, as intermediates for antiarrhythmic and cardiotonic)
RN 136080-33-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid, 3,4-dihydro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 136080-34-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 136080-35-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 136080-36-9 USPATFULL
CN Methanesulfonamide, N-(3,4-dihydro-1-oxospiro[naphthalene-2(1H),4'-piperidin]-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 136112-40-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 6 USPATFULL
AB 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one derivatives are described which are useful as analgesic and anti-fertility agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 81:2388 USPATFULL
TI 2,4a-Ethanobenz[g]isoquinolin-5(1H)-ones and their use as anti-fertility and analgesic agents
IN Farr, Robert A., Cincinnati, OH, United States
Dolfini, Joseph E., Cincinnati, OH, United States
PA Richardson-Merrell Inc., Wilton, CT, United States (U.S. corporation)
PI US 4244955 19810113
AI US 1979-34357 19790430 (6)
DT Utility

FS Granted
EXNAM Primary Examiner: Daus, Donald G.; Assistant Examiner: Springer, D. B.
LREP Stein, William J., Conte, Salvatore R.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1,4,5
DRWN No Drawings
LN.CNT 467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **76448-01-6P 76448-02-7P**
(prepn. and pharmacol. activity of)
RN 76448-01-6 USPATFULL
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro- (9CI) (CA INDEX NAME)



RN 76448-02-7 USPATFULL
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	39.40	180.31

FILE 'CAPLUS' ENTERED AT 16:44:43 ON 13 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 May 2002 VOL 136 ISS 20
FILE LAST UPDATED: 10 May 2002 (20020510/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

CAS roles have been modified effective December 16, 2001. Please
check your SDI profiles to see if they need to be revised. For
information on CAS roles, enter HELP ROLES at an arrow prompt or use
the CAS Roles thesaurus (/RL field) in this file.

=> d his

     (FILE 'HOME' ENTERED AT 16:41:55 ON 13 MAY 2002)

     FILE 'REGISTRY' ENTERED AT 16:43:45 ON 13 MAY 2002
L1   STRUCTURE UPLOADED
L2   188 S L1 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 16:44:16 ON 13 MAY 2002
L3   6 S L2

     FILE 'CAPLUS' ENTERED AT 16:44:43 ON 13 MAY 2002

=> s l2
L4   22 L2

=> s l4 not l3
            22 L2
L5   0 L4 NOT L3

=> d l4 abs bib hitstr 1-22

L4   ANSWER 1 OF 22 CAPLUS COPYRIGHT 2002 ACS
AB   On the basis of a spirocyclic ether screening lead, a series of acyclic
     sulfones have been identified as high-affinity, selective 5-HT2A receptor
     antagonists. Bioavailability lacking in the parent, 1-(2-(2,4-
     difluorophenyl)ethyl)-4-(phenylsulfonyl)piperidine, was introduced by
     using stability toward rat liver microsomes as a predictor of
     bioavailability. By this means, the 4-cyano- and 4-
     carboxamidophenylsulfonyl derivs. were identified as orally bioavailable,
     brain-penetrant analogs suitable for evaluation in animal models.
     Bioavailability was also attainable by N substitution leading to the
     N-phenacyl deriv. IKr activity detected through counterscreening was
     reduced to insignificant levels in vivo with the latter compd.
AN   2001:918064 CAPLUS
DN   136:194114
TI   4-(Phenylsulfonyl)piperidines: Novel, Selective, and Bioavailable 5-HT2A
     Receptor Antagonists
AU   Fletcher, Stephen R.; Burkamp, Frank; Blurton, Peter; Cheng, Susan K. F.;
     Clarkson, Robert; O'Connor, Desmond; Spinks, Daniel; Tudge, Matthew; van
     Niel, Monique B.; Patel, Smita; Chapman, Kerry; Marwood, Rose; Shepheard,
     Sara; Bentley, Graham; Cook, Gina P.; Bristow, Linda J.; Castro, Jose L.;
     Hutson, Peter H.; MacLeod, Angus M.
CS   Merck Sharp and Dohme, The Neuroscience Research Centre, Harlow Essex,
     CM20 2QR, UK
SO   Journal of Medicinal Chemistry (2002), 45(2), 492-503

CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English

IT **400728-91-8**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(prepn. and structure activity of 4-(phenylsulfonyl)piperidines as novel, selective, and bioavailable 5-HT2A receptor antagonists)

RN 400728-91-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



IT **152830-94-9P 400728-94-1P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure activity of 4-(phenylsulfonyl)piperidines as novel, selective, and bioavailable 5-HT2A receptor antagonists)

RN 152830-94-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 400728-94-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine], 1'-[2-(2,4-difluorophenyl)ethyl]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



HCl

IT **136080-34-7**
RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. and structure activity of 4-(phenylsulfonyl)piperidines as novel, selective, and bioavailable 5-HT2A receptor antagonists)

RN 136080-34-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



IT **400729-16-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and structure activity of 4-(phenylsulfonyl)piperidines as novel, selective, and bioavailable 5-HT2A receptor antagonists)

RN 400729-16-0 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 1'-[2-(2,4-difluorophenyl)ethyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2002 ACS

GI



I

AB The title compds. [I; R1 = H, OH; R2 = H, OH; or R1 and R2 together = O; A = a bond, CH2, CH(CH3), CH2CH2, C(CH3)2; R3, R4 = H, halo, alkyl, etc.; R5 = H, alkyl, alkenyl, etc.] and their salts which are potent antagonists of neuronal Na channels, as well as prostaglandin E2 (PGE2) prodn., and therefore are particularly useful for treating, among other indications, neuropathic pain and other CNS disorders such as seizures, were prepd. and formulated. E.g., a multi-step synthesis of I [A = CH2; R1 and R2 together = O; R3, R4 = H; R5 = cyclopropylmethyl] which showed Ki of 876 nM against Na+ channel binding in [3H]BTX assay, was given.

AN 2000:881127 CAPLUS
DN 134:42066
TI Preparation of spiro[naphthalene-2(1H),4'-piperidine] compounds as analgesics
IN Calvet, Alain; Jacobelli, Henri; Puaud, Jocelyne; Roman, Francois J.; Hamon, Jacques; Grouhel, Agnes
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000075116	A2	20001214	WO 2000-EP5783	20000607
W: AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000011427	A	20020326	BR 2000-11427	20000607
NO 2001005966	A	20011206	NO 2001-5966	20011206
PRAI US 1999-137868P	P	19990607		
WO 2000-EP5783	W	20000607		

OS MARPAT 134:42066
IT **312599-84-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as analgesics)
RN 312599-84-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME)



IT **136080-34-7P 152830-56-3P 152830-66-5P**
152830-86-9P 152830-89-2P 152830-94-9P
205120-95-2P 312599-75-0P 312599-76-1P
312599-77-2P 312599-78-3P 312599-79-4P
312599-80-7P 312599-81-8P 312599-82-9P
312599-83-0P 312599-85-2P 312599-86-3P
312599-87-4P 312599-88-5P 312599-89-6P
312599-90-9P 312599-91-0P 312599-92-1P
312599-93-2P 312599-94-3P 312599-97-6P
312599-98-7P 312599-99-8P 312600-00-3P
312600-01-4P 312600-02-5P 312600-03-6P
312600-04-7P 312600-05-8P 312600-06-9P
312600-07-0P 312600-08-1P 312600-09-2P

312600-10-5P 312600-11-6P 312600-12-7P
312600-13-8P 312600-14-9P 312600-15-0P
312600-16-1P 312600-17-2P 312600-18-3P
312600-19-4P 312600-20-7P 312600-21-8P
312600-22-9P 312600-23-0P 312600-24-1P
312600-25-2P 312600-26-3P 312600-27-4P
312600-28-5P 312600-29-6P 312600-30-9P
312600-31-0P 312600-32-1P 312600-33-2P
312600-34-3P 312600-35-4P 312600-36-5P
312600-37-6P 312600-38-7P 312600-39-8P
312600-40-1P 312600-41-2P 312600-42-3P
312600-43-4P 312600-44-5P 312600-45-6P
312600-46-7P 312600-47-8P 312600-48-9P
312600-49-0P 312600-50-3P 312600-53-6P
312600-54-7P 312600-55-8P 312600-56-9P
312600-57-0P 312600-58-1P 312600-59-2P
312600-60-5P 312600-61-6P 312600-62-7P
312600-63-8P 312600-71-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as analgesics)

RN 136080-34-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 152830-56-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-66-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 152830-86-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-89-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-94-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 205120-95-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(phenylmethyl)-(9CI) (CA INDEX NAME)



RN 312599-75-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-76-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-77-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-78-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenyl-2-propenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-79-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-80-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5,7-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-81-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-82-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-83-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-85-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-amino-1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-86-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-chloro-1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-87-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-methyl- (9CI) (CA INDEX NAME)



RN 312599-88-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 312599-89-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-90-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylcarbonyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-91-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[(2-phenylcyclopropyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-92-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[bis(4-fluorophenyl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-93-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-94-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine], 1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-97-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-98-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-99-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-6-fluoro-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-00-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-01-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(1-cyclopropylethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-02-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-pentenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-03-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-04-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(3-phenyl-2-propenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-05-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 312600-06-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 312600-07-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 312600-08-1 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5-methoxy-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 312600-09-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5-methoxy-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 312600-10-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5-methoxy-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-11-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 312600-12-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 312600-13-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 312600-14-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 312600-15-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 312600-16-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 312600-17-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-18-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 312600-19-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 312600-20-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 312600-21-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 312600-22-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-methoxy-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 312600-23-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-methoxy-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 312600-24-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-methoxy-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-25-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 312600-26-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 312600-27-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 312600-28-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 312600-29-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-4-methyl-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 312600-30-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-4-methyl-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 312600-31-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-4-methyl-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-32-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 312600-33-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(2-cyclopropylethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-34-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclobutylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-35-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclohexylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-36-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 312600-37-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-38-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(3,3-diphenylpropyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-39-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 312600-40-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-41-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-42-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-43-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 312600-44-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-45-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5,7-dimethyl- (9CI) (CA INDEX NAME)



RN 312600-46-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 312600-47-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 312600-48-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 312600-49-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-50-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[[(1R,2R)-2-phenylcyclopropyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 312600-53-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-54-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-6-fluoro-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-55-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)



RN 312600-56-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(1-cyclopropylethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-57-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-pentenyl)- (9CI) (CA INDEX NAME)



RN 312600-58-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-59-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-60-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidinium], 1'-(cyclopropylmethyl)-3,4-dihydro-1'-methyl-1-oxo-, iodide (9CI) (CA INDEX NAME)



● I^-

RN 312600-61-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-62-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-amino-1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 312600-63-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-chloro-1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312600-71-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



IT **312600-70-7**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as analgesics)
RN 312600-70-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5,7-dimethyl- (9CI) (CA INDEX NAME)



IT **136080-33-6P 312600-64-9P 312600-65-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as analgesics)
RN 136080-33-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid, 3,4-dihydro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 312600-64-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid, 3,4-dihydro-7-nitro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 312600-65-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2002 ACS
AB An electrochem. and EPR study is reported on two isomeric C60 derivs. contg. a covalently linked free radical TEMPO: a fulleroid (5-6 fusion with opening of the 5-6 bond) and a methanofullerene (6-6 fusion). In line with other C60-based nitroxide derivs., the latter one gives a stable biradical anion upon one-electron redn., and a metastable excited quartet state by visible light photoexcitation. Both species have characteristic EPR spectra. For the fulleroid deriv., the first redn. step is not chem. reversible and no excited state EPR signal is obsd. after LASER excitation. Electrochem. and spectroelectrochem. techniques indicate that fulleroid to methanofullerene conversion takes place by photoexcitation and, more interesting, upon injection of a single electron, contrary to the cases of other fulleroids so far reported.
AN 1999:780845 CAPLUS
DN 132:107631
TI Tempo-C61: An Unusual Example of Fulleroid to Methanofullerene Conversion
AU Ceroni, Paola; Conti, Fosca; Corvaja, Carlo; Maggini, Michele; Paolucci, Francesco; Roffia, Sergio; Scorrano, Gianfranco; Toffoletti, Antonio
CS Dipartimento di Chimica G. Ciamician, Universita di Bologna, Bologna, 40126, Italy

SO Journal of Physical Chemistry A (2000), 104(1), 156-163
CODEN: JPCAFH; ISSN: 1089-5639
PB American Chemical Society
DT Journal
LA English

No.

IT **169477-24-1**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
(photochem. and electrochem. fulleroid .fwdarw. methanofullerene isomerization of a spiro-fused fullerene-TEMPO nitroxide)
RN 169477-24-1 CAPLUS
CN Spiro[1,2(2a)-homo[5,6]fullerene-C60-Ih-2a,4'-piperidin]-1'-yloxy, 2',2',6',6'-tetramethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2002 ACS

AB We have studied the reactivity of N,O-ketene N-1,3-butadienyl-N-alkyl-O-silyl acetals (Z)-RCH:CH(OSiMe2CMe3)N(R1)CH:CHCH:CH2 (R = Me2CH, PhCH2, 9-anthracenylmethyl, 4-MeOC6H4CH2; R1 = Me, 4-MeOC6H4, H2C:CH) (I) with C60 proceeding through a tandem process to give tricyclic octahydroquinolinyl fullerene adducts. Deprotonation of the tricyclic octahydroquinolinyl fullerene adducts with sodium hydride and addn. of alkylating agents such as Me iodide, allyl bromide, or benzyl bromide yield adducts alkylated on the fullerene. The addn. order of these tandem reactions has been evaluated. The initial nucleophilic Michael-like addn. of I proceeds unusually fast at 25.degree.C, followed by an intramolecularly accelerated Diels - Alder step that is highly diastereoselective. The structures of the tricyclic octahydroquinolinyl fullerene adducts were detd. from the 1H and 13C NMR shifts and from H - H coupling patterns, while their stereochem. was deduced from 2D T-ROESY NMR expts. The proposed mechanism for the nucleophilic addn. involves single electron transfer followed by radical anion - radical cation recombination. Computational investigations of the reaction pathways, transition states, and conformational energies have been carried out to corroborate the exptl. data.

AN 1999:735295 CAPLUS
DN 132:137266

TI Tandem nucleophilic addition/Diels - Alder reaction of N-butadienyl N,O-Ketene silyl acetals with C60: stereoselective formation of bicyclic octahydroquinolino-1,2,3,4-tetrahydrobuckminsterfullerenes and combined NMR spectroscopic and computational evaluation of the functionalization reactions

AU Rubin, Yves; Ganapathi, Padma S.; Franz, Andreas; An, Yi-Zhong; Qian, Wenyuan; Neier, Reinhard

CS Department of Chemistry and Biochemistry, University of California. Los Angeles, Los Angeles, CA, 90095-1569, USA

SO Chemistry--A European Journal (1999), 5(11), 3162-3184
CODEN: CEUJED; ISSN: 0947-6539

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

OS CASREACT 132:137266

IT **256652-81-0**
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)
(calcd. structures and energies for a Cope rearrangement of octahydroquinolinyl fullerene derivs.)

RN 256652-81-0 CAPLUS

CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 3'-ethenyl-6',8'a-dihydro-1',12-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A





IT **256652-53-6 256652-54-7 256652-55-8**
256652-56-9 256652-57-0 256652-58-1
256652-61-6 256652-62-7 256652-63-8
RL: PRP (Properties)
(calcd. structures for regioisomeric products in electrophilic addns. to octahydroquinolinyl fullerene anions)
RN 256652-53-6 CAPLUS
CN 1'H,10H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 256652-54-7 CAPLUS
CN 1'H,10H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3',10-trimethyl-, stereoisomer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 256652-55-8 CAPLUS
CN 1'H,10H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-10-(trimethylsilyl)-, stereoisomer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 256652-56-9 CAPLUS
CN 1'H,3H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



RN 256652-57-0 CAPLUS
CN 1'H,3H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3,3'-trimethyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



RN 256652-58-1 CAPLUS
CN 1'H,3H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-3-(trimethylsilyl)-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





RN 256652-61-6 CAPLUS
CN 1'H,27H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 256652-62-7 CAPLUS
CN 1'H,27H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3',27-trimethyl-, stereoisomer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 256652-63-8 CAPLUS
CN 1'H,27H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-27-(trimethylsilyl)-, stereoisomer (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **256652-40-1 256652-42-3 256652-44-5**
RL: PRP (Properties)
(calcd. structures for regioisomeric products in the regioselective electrophilic addn. of electrophiles to octahydroquinolinyl fullerene anions)
RN 256652-40-1 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 256652-42-3 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3',12-trimethyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 256652-44-5 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-12-(trimethylsilyl)-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **256652-52-5**
RL: PRP (Properties)
(calcd. structures for the fullerene anion intermediate in the

regioselective electrophilic addn. of electrophiles to octahydroquinolinyl fullerene anions)

RN 256652-52-5 CAPLUS

CN 1'H,3H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-, ion(1-), stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



IT **183507-62-2 256654-57-6 256654-58-7**
RL: PRP (Properties)
(calcd. structures of intermediates and influences on stereoselectivity in the Diels-Alder cycloaddn. of a diene tethered to C60)
RN 183507-62-2 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-(4-methoxyphenyl)-1'-[(4-methoxyphenyl)methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A

PAGE 2-A



PAGE 3-A



RN 256654-57-6 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-methyl-1'-(1-methylethyl)-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 256654-58-7 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1',3'-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A





IT **256652-82-1P**
RL: PNU (Preparation, unclassified); PREP (Preparation)
(failed prepn. of a fullerene dipeptide mimetic by ozonolysis of the cyclohexene double bond of an octahydroquinolinyl fullerene)
RN 256652-82-1 CAPLUS
CN [5,6]Fullereno-C60-Ih-[1,2-c]pyridine-9(12H)-acetic acid, 2'-carboxy-1',2',5',6'-tetrahydro-5'-methyl-1'-(1-methylethyl)-6'-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **183311-48-0P 183311-52-6P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of fullerene derivs. by addn. and intramol. Diels-Alder cycloaddn. of N,O-silyl ketene acetals to C60)
RN 183311-48-0 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one,

6',8'a-dihydro-3'-methyl-1'-(1-methylethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 183311-52-6 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 3'-ethenyl-6',8'a-dihydro-1'-(1-methylethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





IT **183311-49-1P 183311-50-4P 183311-51-5P**
183507-61-1P 256652-24-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of fullerene derivs. by addn. and intramol. Diels-Alder cycloaddn. of N,O-silyl ketene acetals to C60)

RN 183311-49-1 CAPLUS

CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-methyl-1'-(phenylmethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 183311-50-4 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1'-(9-anthracenylmethyl)-3'-methyl-, stereoisomer (9CI)

(CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 183311-51-5 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one,
6',8'a-dihydro-3'-(4-methoxyphenyl)-1'-[(4-methoxyphenyl)methyl]-,
stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 2-A



PAGE 3-A



RN 183507-61-1 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-(4-methoxyphenyl)-1'-[(4-methoxyphenyl)methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A

PAGE 2-A



PAGE 3-A



RN 256652-24-1 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-(4-methoxyphenyl)-1'-[(4-methoxyphenyl)methyl]-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A





IT **256652-36-5P 256652-38-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of fullerene hydroperoxides and alcs. by photochem. oxygenation of octahydroquinolinyl fullerenes)
RN 256652-36-5 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 8',8'a-dihydro-8'-hydroperoxy-3'-methyl-1'-(1-methylethyl)-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 256652-38-7 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 8',8'a-dihydro-8'-hydroxy-3'-methyl-1'-(1-methylethyl)-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 157 THERE ARE 157 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2002 ACS

AB The Similarity Principle provides the conceptual framework behind most modern approaches to library sampling and design. However, it is often the case that compds. which appear to be very similar structurally may in fact exhibit quite different activities toward a given target. Conversely, some targets recognize a wide variety of mols. and thus bind compds. that have markedly different structures. Affinity fingerprints largely overcome the difficulties assocd. with selecting compds. on the basis of structure alone. By describing each compd. in terms of its binding affinity to a set of functionally dissimilar proteins, fundamental factors relevant to binding and biol. activity are automatically encoded. We demonstrate how affinity fingerprints may be used in conjunction with simple algorithms to select active-enriched diverse training sets and to efficiently ext. the most active compds. from a large library.

AN 1998:612813 CAPLUS

DN 129:339453

TI Bioactive Diversity and Screening Library Selection via Affinity Fingerprinting

AU Dixon, Steven L.; Villar, Hugo O.

CS Telik Inc., South San Francisco, CA, 94080, USA

SO J. Chem. Inf. Comput. Sci. (1998), 38(6), 1192-1203
CODEN: JCISD8; ISSN: 0095-2338

PB American Chemical Society

DT Journal

LA English

IT **10199-09-4**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(bioactive diversity and screening library selection via affinity fingerprinting)

RN 10199-09-4 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidine]-3',5'-dicarbonitrile, 3,4-dihydro-7-methoxy-2',6'-dioxo- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2002 ACS

GI



I



II

AB The invention relates to the claimed title compds. I [n = 3-5; B = C or N; R1, R2, R3, R4 = H, halo, NO2, NH2, (un)substituted alkyl, alkoxy, aryl, heteroaryl, etc.; R5, R6, R7, R8 = H, alkyl, alkenyl, alkoxy; Z = O, S, CH2, NH, NMe] and analogs. Also disclosed are the synthesis and use of the compds. as selective .alpha.1C-adrenergic receptor antagonists. The primary application of the compds. is in the treatment of benign prostatic hypertrophy (BPH). The compds. selectively relax smooth muscle tissue enriched in the .alpha.1C receptor subtype without inducing orthostatic hypotension. The compds. provide acute relief of BPH by permitting less hindered urine flow. I and analogs are also useful in combination with human 5.alpha.-reductase inhibitors, providing both acute and chronic relief from the effects of BPH. Approx. 130 specific invention compds. are disclosed. The cloning and use of a cDNA for a human .alpha.1C adrenoceptor in an in vitro assay is described. For instance, alkylation of 1-(4-piperidinyl)-3-benzoxazolin-2-one.HCl (prepd. in 4 steps) with 2-(4-bromobutyl)-1,1-dioxido-1,2-benzisothiazol-3(2H)-one in the presence of (i-Pr)2NEt in DMF gave 40% title compd. II. Selected compds. showed nanomolar or subnanomolar affinity for human .alpha.1C receptor subtype while showing 30-fold lower affinity for human .alpha.1A and .alpha.1B subtypes (no data).

AN 1998:392146 CAPLUS
DN 129:54361
TI Preparation of benzisothiazolones and analogs as .alpha.1C-adrenergic receptor antagonists
IN Huff, Joel R.; Lee, Hee-yoon; Nerenberg, Jennie B.; Thompson, Wayne J.; Bell, Ian M.
PA Merck and Co., Inc., USA
SO U.S., 57 pp. Cont.-in-part of U. S. Ser. No. 229,276, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

 not good

PI US 5760054 A 19980602 US 1996-722001 19961001
WO 9528397 A1 19951026 WO 1995-US4590 19950413
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRAI US 1994-229276 19940413
WO 1995-US4590 19950413

OS MARPAT 129:54361

IT **173842-22-3P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzisothiazolones and analogs as .alpha.1C-adrenergic antagonists)

RN 173842-22-3 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[4-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



HCl

IT **136080-34-7**
RL: RCT (Reactant)
(prepn. of benzisothiazolones and analogs as .alpha.1C-adrenergic antagonists)

RN 136080-34-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2002 ACS

AB The title compd., spipethiane, was synthesized and evaluated for in vitro activity on .sigma.1, .sigma.2 and .sigma.3, 5-HT, D2, M2 and M3, .alpha.1A and .alpha.1B, opioid and PCP receptors. Spipethiane displayed high affinity toward .sigma.1 receptors and more than two orders of magnitude lower affinity for both .sigma.2 and .sigma.3 receptors while being devoid of affinity for the other receptor systems so far investigated. Owing to its high .sigma.1 selectivity, it emerged as a useful pharmacol. tool for the characterization of this receptor population and also for the design of new therapeutic agents for the

treatment of various mental and motor disorders.
AN 1998:269382 CAPLUS
DN 128:252920
TI 1'-Benzyl-3,4-dihydrospiro[2H-1- benzothiopyran-2,4'-piperidine] (Spipethiane), a Potent and Highly Selective .sigma.1 Ligand
AU Quaglia, Wilma; Giannella, Mario; Piergentili, Alessandro; Pigini, Maria; Brasili, Livio; Di Toro, Rosanna; Rossetti, Lorena; Spampinato, Santi; Melchiorre, Carlo
CS Department of Chemical Sciences, University of Camerino, Camerino, 62032, Italy
SO J. Med. Chem. (1998), 41(10), 1557-1560
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT **205122-15-2**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(spipethiane, a potent and highly selective .sigma.1 ligand)
RN 205122-15-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(phenylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 205120-95-2
CMF C21 H23 N O



CM 2

CRN 144-62-7
CMF C2 H2 O4



L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2002 ACS
AB A series of C60 derivs. substituted with the nitroxide group 2,2,6,6-tetramethylpiperidine-1-oxyl have been synthesized. A detailed EPR and ENDOR study of the neutral radicals and of their redn. products is reported. All the neutral species give EPR spectra consisting of a main triplet of lines with .apprx.15 G splitting by the 14N nucleus, typical of nitroxide radicals. Some of them show addnl. well-resolved splittings by Me and methylene protons, which are discussed in relation to the conformation of the nitroxide ring. When the compds. are progressively reduced under vacuum by contact with an alkali metal mirror, new EPR lines

are obsd.; a 1:1:1 triplet with a splitting const. half that of a nitroxide radical and g = 2.0030 is attributed to biradical anions where one electron is located in the fullerene moiety and experiences a strong exchange coupling with the nitroxide unpaired electron. Frozen soln. spectra of these species allow the detn. of the electron-electron dipolar interaction parameters which are compared with theor. MO calcns. The exptl. values agree with a spin distribution of one unpaired electron mostly in the equatorial plane of the fullerene. Another single line which appears in the spectrum as the redn. proceeds further on (g = 1.9999) is attributed to a new species: possibly a substituted fullerene radical anion in which the nitroxide group is irreversibly reduced.

AN 1997:21017 CAPLUS
DN 126:89026
TI Synthesis and EPR Studies of Radicals and Biradical Anions of C60 Nitroxide Derivatives
AU Arena, Francesca; Bullo, Federico; Conti, Fosca; Corvaja, Carlo; Maggini, Michele; Prato, Maurizio; Scorrano, Gianfranco
CS Dipartimento di Chimica Fisica, Universita di Padova, Padua, I-35131, Italy
SO J. Am. Chem. Soc. (1997), 119(4), 789-795
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
IT **169477-24-1**
RL: PRP (Properties); RCT (Reactant)
(synthesis and EPR studies of radicals and biradical anions of C60 nitroxide derivs.)
RN 169477-24-1 CAPLUS
CN Spiro[1,2(2a)-homo[5,6]fullerene-C60-Ih-2a,4'-piperidin]-1'-yloxy, 2',2',6',6'-tetramethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI For diagram(s), see printed CA Issue.
AB The authors have studied the reactivity of the N,O-ketene N-1,3-butadienyl-N-alkyl-O-silylacetals (1a-e; shown as I, R = iso-Pr, PhCH2, 9-anthrylmethyl, R1 = Me; R = 4-MeOC6H4CH2, R1 = 4-MeOC6H4; R = iso-Pr, R1 = CH:CH2) with C60 which proceeds through a tandem process to give bicyclic amide derivs. of fullerenes (2a-e; shown as II, R and R1 same as above, A = fullerene C60 moiety) with high diastereoselectivity. The addn. order of these tandem reactions was evaluated. The structures of 2a-e were detd. from the 1H and 13C NMR shifts and from the H-H coupling patterns, while the stereochem. was deduced from 2-dimensional T-ROESY NMR expts. The proposed mechanism for the Michael-type addn. step is a single electron transfer, and the source of the C60-attached proton is discussed.
AN 1996:570821 CAPLUS
DN 125:328460
TI Tandem cycloadditions of N,O-ketene N-1,3-butadienyl-N-alkyl-O-silylacetals with C60: a straightforward stereoselective synthesis of bicyclic derivatives of 1,2,3,4-tetrahydrobuckminsterfullerene
AU Franz, Andreas; An, Yi-Zhong; Ganapathi, Padma S.; Neier, Reinhard; Rubin, Yves
CS Dep. Chem. Biochem., Univ. California, Los Angeles, CA, 90095-1569, USA

SO Proc. - Electrochem. Soc. (1996), 96-10(Recent Advances in the Chemistry and Physics of Fullerenes and Related Materials, Vol. 3), 1326-1341
CODEN: PESODO; ISSN: 0161-6374
DT Journal
LA English
OS CASREACT 125:328460
IT **183311-48-0P 183311-49-1P 183311-50-4P 183311-51-5P 183311-52-6P 183507-61-1P 183507-62-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 183311-48-0 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-methyl-1'-(1-methylethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 183311-49-1 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-methyl-1'-(phenylmethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A





RN 183311-50-4 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-1'-(9-anthracenylmethyl)-3'-methyl-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 183311-51-5 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one,
6',8'a-dihydro-3'-(4-methoxyphenyl)-1'-[(4-methoxyphenyl)methyl]-,

stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A

PAGE 2-A



PAGE 3-A



RN 183311-52-6 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 3'-ethenyl-6',8'a-dihydro-1'-(1-methylethyl)-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 183507-61-1 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-(4-methoxyphenyl)-1'-[(4-methoxyphenyl)methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A

PAGE 2-A



PAGE 3-A



RN 183507-62-2 CAPLUS
CN 1'H,12H-[5,6]Fullereno-C60-Ih-[2,1,9-de]quinolin-2'(3'H)-one, 6',8'a-dihydro-3'-(4-methoxyphenyl)-1'-[(4-methoxyphenyl)methyl]-, stereoisomer (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A

PAGE 2-A



PAGE 3-A



L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2002 ACS
AB The sodium salt of TEMPON tosylhydrazone was pyrolyzed in chlorobenzene in the presence of C60 to give the adducts C60(TEMPO)n (n = 1-3) [TEMPO = 2,2,6,6-tetramethylpiperidin-1-oxyl, TEMPON = 4-oxo-TEMPO]. The adducts were isolated by gel permeation chromatog., and characterized by mass, IR, UV/visible, and ESR spectroscopies. The structure of C60(TEMPO) is an open [5,6]. The magnetic measurements showed the radical purity.
AN 1996:212785 CAPLUS
DN 124:343071
TI Synthesis and characterization of C60 derivatives possessing TEMPO radicals
AU Ishida, Takayuki; Shinozuka, Koji; Nogami, Takashi; Kubota, Masayuki; Ohashi, Mamoru
CS Dep. Appl. Phys. Chem., Univ. Electro-Communications, Chofu, 182, Japan
SO Tetrahedron (1996), 52(14), 5103-12
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 124:343071
IT **176789-95-0P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn., magnetic susceptibility and electrochem. oxidn. and redn. of)
RN 176789-95-0 CAPLUS
CN Spiro[1,2(2a)-homo[5,6]fullerene-C60-Ih-2a,4'-piperidin]-1'-yloxy, 2',2',6',6'-tetramethyl-, compd. with carbon disulfide (9CI) (CA INDEX NAME)

CM 1

CRN 169477-24-1
CMF C69 H16 N O

PAGE 1-A



PAGE 2-A



CM 2

CRN 75-15-0
CMF C S2



L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB Title compds. such as I (R1, R2, R3, R4 = H, NO2, NH2, etc.; R5, R6, R7, R8 = H, alkyl, alkenyl, alkoxy, etc.) and II, effective testosterone reductase inhibitors useful in treatment of benign prostatic hyperplasia, were prepd. Alkylation of 1-(4-piperidinyl)-3-benzoxazolin-2-one.HCl with 2-(4-bromobutyl)-1,1-dioxo-1,2-benzothiazol-3(2H)-one in the presence of (i-Pr)2NEt in DMF afforded 40% I (R1-R8 = H). Title compds. are effective at 0.001 mg/kg - 7 mg/kg per day in humans.
AN 1995:998362 CAPLUS
DN 124:176079
TI Preparation of heterocycles as .alpha.1c adrenergic receptor antagonists
IN Huff, Joel R.; Lee, Hee-Yoon; Nerenberg, Jennie B.; Thompson, Wayne J.
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 209 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9528397	A1	19951026	WO 1995-US4590	19950413
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2187767	AA	19951026	CA 1995-2187767	19950413
	AU 9523566	A1	19951110	AU 1995-23566	19950413
	AU 688498	B2	19980312		
	EP 755392	A1	19970129	EP 1995-917565	19950413
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09512016	T2	19971202	JP 1995-527097	19950413
	US 5760054	A	19980602	US 1996-722001	19961001
PRAI	US 1994-229276		19940414		
	WO 1995-US4590		19950413		

OS MARPAT 124:176079
IT **173842-22-3P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocycles as .alpha.1c adrenergic receptor antagonists)
RN 173842-22-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[4-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



IT **136080-34-7**
RL: RCT (Reactant)
(prepn. of heterocycles as .alpha.1c adrenergic receptor antagonists)
RN 136080-34-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2002 ACS

AB A spin-labeled reagent C60(TEMPO) (TEMPO = 2,2,6,6-tetramethylpiperidin-1-oxyl) was synthesized, purified by LC, and characterized by spectroscopic, magnetic and electrochem. measurements.

AN 1995:836638 CAPLUS
DN 123:285719

TI Fullerene spin label. Synthesis and characterization of the [60]fullerene-substituted TEMPO radical

AU Ishida, Takayuki; Shinozuka, Koji; Kubota, Masayuki; Ohashi, Mamoru; Nogami, Takashi
CS Dep. Applied Physics and Chemistry, Univ. Electro-Communications, Chofu, 182, Japan

SO J. Chem. Soc., Chem. Commun. (1995), (18), 1841-2
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English

IT **169477-24-1P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn., ESR and UV-visible spectra, magnetic susceptibility and electrochem. redox of fullerene piperidinoxyl deriv. spin label)

RN 169477-24-1 CAPLUS

CN Spiro[1,2(2a)-homo[5,6]fullerene-C60-Ih-2a,4'-piperidin]-1'-yloxy, 2',2',6',6'-tetramethyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A

L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI





AB Spiro compds. I [X = O or CH2; one of R1 or R2 = H; other = NHAc, OH, NH2, or NHCOCH(NH2)CH2Ph; R3 = CH2CH2C6H4CN-4 or group Q] and their pharmaceutically acceptable salts, hydrates, or crystal forms, are Class III antiarrhythmic agents. For example, Et N-benzoylisonipecotate underwent a sequence of lithiation with LDA, alkylation with 4-MeOC6H4CH2Cl, sapon. of the Et ester, and homologation of the acid group using diazomethane, to give intermediate II. This acid was then cyclized, debenzoylated, N-alkylated, reduced at the formed keto function to an alc., and treated with H2SO4 in MeCN, to give title compd. III. In an in vitro test for increase of effective refractory period in isolated ferret heart muscle, most I had an EC50 of .ltoreq. 10 .mu.M, whereas sotalol had an EC25 of approx. 20 .mu.M. Examples include 16 syntheses and 2 pharmaceutical prepns.

AN 1995:793000 CAPLUS

DN 124:55812

TI Spirocycles useful as Class III antiarrhythmic agents.

IN Claremon, David A.; Ponticello, Gerald S.; Selnick, Harold G.

PA Merck and Co., Inc., USA

SO U.S., 18 pp.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5439914	A	19950808	US 1994-198940	19940218
	WO 9522548	A1	19950824	WO 1995-US1960	19950215

W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ

RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	CA 2182733	AA	19950824	CA 1995-2182733	19950215
	AU 9519208	A1	19950904	AU 1995-19208	19950215
	EP 745086	A1	19961204	EP 1995-911762	19950215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09509177	T2	19970916	JP 1995-521910	19950215
PRAI	US 1994-198940		19940218		
	WO 1995-US1960		19950215		

OS MARPAT 124:55812

IT **171797-76-5P 171797-77-6P 171797-78-7P 171797-79-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (intermediate; prepn. of spirocycles as Class III antiarrhythmic agents)

RN 171797-76-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-4(3H)-one, 1'-benzoyl-6-methoxy- (9CI) (CA INDEX NAME)



RN 171797-77-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-4(3H)-one, 6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-78-7 CAPLUS
CN Benzonitrile, 4-[2-(3,4-dihydro-6-methoxy-4-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-79-8 CAPLUS
CN Benzonitrile, 4-[2-(3,4-dihydro-6-methoxy-4-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]- (9CI) (CA INDEX NAME)



IT **171797-63-0P**
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-63-0 CAPLUS
CN Benzonitrile, 4-[2-(3,4-dihydro-4-hydroxy-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]- (9CI) (CA INDEX NAME)



IT **171797-64-1P 171797-65-2P 171797-66-3P**
171797-67-4P 171797-68-5P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-64-1 CAPLUS

CN Benzonitrile, 4-[2-(3,4-dihydro-4-hydroxy-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-65-2 CAPLUS
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 171797-66-3 CAPLUS
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-67-4 CAPLUS
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, (S)- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 171797-68-5 CAPLUS
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2002 ACS
AB Title compds. R3NH(CH2)nCR1R2(CH2)mR4 [I; R1, R2 = C1-6 alkyl or alkoxy, (substituted) Ph, OH, trihalomethyl, pyridinyl, thienyl; R1R2 form with the attached carbon a (substituted) C4-7 cycloalkyl, C4-7 benzocycloalkyl, (substituted) 4-piperidinyl; R3 = PhSO2 optionally substituted on Ph by C1-6 alkyl, naphthylsulfonyl, C1-6 alkyl, alkylaminocarbonyl, C1-6 acyl; R4 = CH:CH(CH2)pCO2H or CH2CH2(CH2)pCO2H (p = 0-3); n, m = 0-2], their isomers and salts, are prepd. as thromboxane A2 receptor antagonists and as inhibitors of thromboxane A2 synthase. Preparative methods are delineated for compds. I starting from either R1CHR2CHCN or R1CHR2CO2Et. Thus, 1-(2,2-dimethoxyethyl)cyclopentanecarbonitrile (prepn. given) was converted to sodium (4Z)-8-[(4-chlorophenyl)sulfonamido]-7,7-tetramethylene-4-octenoate in 5 steps. The thromboxane A2 receptor antagonist activity of compds. I (8 examples) was expressed as IC50 of inhibition of platelet aggregation in humans induced by U46619 and was in the range 8.10 .times. 10-8 to 8.10 .times. 10-7 M. Pharmaceutical compns. of compds. I are claimed (1 example).
AN 1994:270075 CAPLUS
DN 120:270075
TI Preparation of aminoalkenecarboxylic acid derivatives and their

pharmaceutical compositions as thromboxane A2 receptor antagonists
IN Lavielle, Gilbert; Hautefaye, Patrick; Laubie, Michel; Verbeuren, Tony
PA Adir et Compagnie, Fr.
SO Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 570263	A1	19931118	EP 1993-401174	19930507
	EP 570263	B1	19971203		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2691146	A1	19931119	FR 1992-5905	19920515
	FR 2691146	B1	19980102		
	AT 160771	E	19971215	AT 1993-401174	19930507
	ES 2112404	T3	19980401	ES 1993-401174	19930507
	CA 2096293	AA	19931116	CA 1993-2096293	19930514
	CA 2096293	C	19990323		
	AU 9338555	A1	19931118	AU 1993-38555	19930514
	AU 661576	B2	19950727		
	ZA 9303380	A	19931210	ZA 1993-3380	19930514
	JP 06041052	A2	19940215	JP 1993-113226	19930514
	JP 2506261	B2	19960612		
	US 5436343	A	19950725	US 1993-62080	19930514
PRAI	FR 1992-5905		19920515		

OS MARPAT 120:270075
IT **154678-95-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, in prepn. of aminoalkenecarboxylic acid thromboxane A2 receptor antagonist)
RN 154678-95-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine]-3',5'-dicarbonitrile, 3,4-dihydro-2',6'-dioxo-, ammonium salt (9CI) (CA INDEX NAME)



● NH_3

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB .sigma. Receptor ligands have been proposed to be potential antipsychotic drugs based on their activity profile in animal behavioral models and their indirect modulation of dopaminergic function. DuP 734 (I) is a combined antagonist of .sigma.-1 and serotonin 5HT2 receptors, which has been entered into phase I clin. trials as a potential antipsychotic drug. Tetralins were prepd. to det. whether restriction of the conformation of I and its analogs may lead to differences in binding selectivity or in vivo profile. The syntheses and the structure-activity relationships of these compds. are reported. A reduced deriv. (II) had high affinity for .sigma.-1 and serotonin 5HT2 receptors as well as excellent oral activity in some animal antipsychotic models. Furthermore, II failed to cause catalepsy in the rat up to 90 mg/kg (oral).

AN 1994:124142 CAPLUS

DN 120:124142

TI Piperidinyltetralin .sigma. Ligands

AU Gilligan, Paul J.; Kergaye, Ahmed A.; Lewis, Bryan M.; McElroy, John F.

CS CNS Diseases Research, DuPont Merck Pharmaceutical Company, Wilmington, DE, 19880-0353, USA

SO J. Med. Chem. (1994), 37(3), 364-70
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

IT **152830-66-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of)

RN 152830-66-5 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



IT **152830-56-3P 152830-80-3P 152830-81-4P**
152830-82-5P 152830-84-7P 152830-85-8P
152830-86-9P 152830-88-1P 152830-89-2P
152830-90-5P 152830-91-6P 152830-93-8P

152830-94-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as .sigma.-receptor ligand)
RN 152830-56-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-80-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[(4-fluorophenyl)methyl]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-81-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-82-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[(4-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-84-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[[4-(trifluoromethyl)phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152830-83-6
CMF C22 H22 F3 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



RN 152830-85-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[(4-nitrophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-86-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-88-1 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-naphthalenylmethyl)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152830-87-0
CMF C25 H25 N O



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



RN 152830-89-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-90-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[4-(4-fluorophenyl)-4-oxobutyl]-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-91-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-methyl-, hydrochloride (9CI) (CA INDEX NAME)



HCl

RN 152830-93-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6,8-difluoro-3,4-dihydro-1'-(2-phenylethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152830-92-7
CMF C22 H23 F2 N O



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 152830-94-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI For diagram(s), see printed CA Issue.
AB Title compds. [I; Ar = benzo, thieno, furo, or pyrido ring; B = 5-8-membered ring; X, Y, Z = O, CO, CH(OR5), NR6, CHNR7R8, CH, N, bond, (CR4R5)n, etc.; R1-R3 = H, OH, (substituted) alkyl, Ph, alkoxy, amino, NO2, halo, alkylcarbonyl, carbamoyl, CF3, aminosulfonyl, etc.; adjacent R1R2Ar = Q1, Q2, etc.; R = (CR4R5)mQ(CR4R5)q; R4, R5 = H, alkyl; R6 = H, alkyl, arylcarbonyl, alkylcarbonyl, (CH2)nC6H4R10; R10 = NO2, alkyl, alkoxy, halo, CF3, H; R7, R8 = H, (substituted) alkyl, alkylcarbonyl, arylcarbonyl; R7R8N = (substituted) satd. 5- or 6-membered ring; M = H, OH, carboxy, alkoxycarbonyl, carbamoyl, amino, halo, cycloalkyl, R3sAr2; Ar2 = carbocyclic, heterocyclic ring; Q = bond, O, CO, CH(OH), NR5, S(O)n; n = 0-2; n, q = 0-5; s = 1-3], were prepd. as antiarrhythmics (no data). Thus, a mixt. of 2-mercaptothiophene, N-benzoyl-4-(carboxymethylidene)piperidine, and Et3N in THF was refluxed 4 h to give N-benzoyl-4-carboxymethyl-4-(2-thienothio)piperidine. The latter in

CH2Cl2 at 10.degree. was treated with DMF, (COCl)2, and then F3CSO2OH followed by warming to room temp. to give 1-benzoylspiro(piperidine-4,6'(6H)thieno[2,3-b]thiopyran)-4'(5'H)-one. The latter was treated with HNO3/Ac2O, refluxed in 6N HCl/MeOH, and condensed with 2-vinylpyridine in MeOH/H2O contg. NaOAc.3H2O to give 2'-nitro-1-[2-(2-pyridyl)ethyl]spiro(piperidine-4,6'-(6H)thieno[2,3-b]thiopyran)-4'(5'H)-one.

AN 1992:20938 CAPLUS
DN 116:20938
TI Preparation of arylheterocyclylspiropiperidines as class III antiarrhythmics and cardiotonics
IN Baldwin, John J.; Claremon, David A.; Elliott, Jason M.; Ponticello, Gerald S.; Remy, David C.; Selnick, Harold G.
PA Merck and Co., Inc., USA
SO Eur. Pat. Appl., 162 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 431943	A2	19910612	EP 1990-313262	19901206
	EP 431943	A3	19920325		
	EP 431943	B1	19980715		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2031633	AA	19910609	CA 1990-2031633	19901206
	AT 168377	E	19980815	AT 1990-313262	19901206
	ES 2118715	T3	19981001	ES 1990-313262	19901206
	FI 9006045	A	19910609	FI 1990-6045	19901207
	NO 9005306	A	19910610	NO 1990-5306	19901207
	AU 9067873	A1	19910613	AU 1990-67873	19901207
	CN 1053613	A	19910807	CN 1990-110421	19901207
	ZA 9009836	A	19910925	ZA 1990-9836	19901207
	JP 04217960	A2	19920807	JP 1990-419271	19901207
	JP 07047576	B4	19950524		
	US 5206240	A	19930427	US 1991-709686	19910603
	AU 9463297	A1	19940721	AU 1994-63297	19940524
	CN 1110685	A	19951025	CN 1995-100709	19950106
	US 5633247	A	19970527	US 1995-498525	19950705
PRAI	US 1989-447950		19891208		
	US 1990-612091		19901116		
	US 1991-709686		19910603		
	US 1992-998321		19921230		

OS MARPAT 116:20938
IT **136081-76-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antiarrhythmic and cardiotonic)
RN 136081-76-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **136074-77-6P 136074-78-7P 136074-79-8P**
136074-80-1P 136074-81-2P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as class III antiarrhythmic and cardiotonic)
RN 136074-77-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-78-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-79-8 CAPLUS
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]- (9CI) (CA INDEX NAME)



RN 136074-80-1 CAPLUS

CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 136074-81-2 CAPLUS
CN Methanesulfonamide, N-[4-[2-[3,4-dihydro-7-[(methylsulfonyl)amino]-1-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



IT **136080-33-6P 136080-34-7P 136080-35-8P**
136080-36-9P 136112-40-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediates for antiarrhythmic and cardiotonic)
RN 136080-33-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid, 3,4-dihydro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 136080-34-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 136080-35-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 136080-36-9 CAPLUS
CN Methanesulfonamide, N-(3,4-dihydro-1-oxospiro[naphthalene-2(1H),4'-piperidin]-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 136112-40-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB Imidazolium methylides such as imidazolium dicyanomethylide and bis(ethoxycarbonyl)methylide react with the methylenecyclopropenes with unsatd. substituents at the 4-position in the fashion of double cycloaddn. reaction, leading to the novel cage compds., e.g. I, which involves an intermol. 1,3-dipolar cycloaddn. reaction and an intramol. Diels-Alder reaction.

AN 1984:22615 CAPLUS

DN 100:22615

TI Double cycloaddition reaction of imidazolium methylides. Intermolecular 1,3-dipolar and intramolecular Diels-Alder cycloaddition reactions

AU Tsuge, Otohiko; Kanemasa, Shuji; Takenaka, Shigeori

CS Interdiscip. Grad. Sch. Eng. Sci., Kyushu Univ., Kasuga, 816, Japan

SO Bull. Chem. Soc. Jpn. (1983), 56(7), 2073-6
CODEN: BCSJA8; ISSN: 0009-2673

DT Journal

LA English

IT **87446-60-4P 87454-55-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 87446-60-4 CAPLUS

CN 6H-2,5,5a-Methenobenzo[g]pyrrolo[1,2,3-cd]benzimidazole-4,4(5H)-dicarboxylic acid, 6-cyano-1,2,10b,10c-tetrahydro-1-methyl-5,11-diphenyl-, diethyl ester, (2.alpha.,5.alpha.,5a.alpha.,6.beta.,10b.beta.,10c.beta.,11S*)- (9CI) (CA INDEX NAME)



RN 87454-55-5 CAPLUS

CN 6H-2,5,5a-Methenobenzo[g]pyrrolo[1,2,3-cd]benzimidazole-4,4,6(5H)-tricarbonitrile, 1,2,10b,10c-tetrahydro-1-methyl-5,11-diphenyl-, (2.alpha.,5.alpha.,5a.alpha.,6.beta.,10b.beta.,10c.beta.,11S*)- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I



II



III



IV

AB Cage compds. (I, II, R = R1 = CN, CO2Et; R = H, R1 = CO2Me, CO2Et, Bz) were prepd. in 16-89% yields by the title reaction of III with IV (R2 = Ph, Bz).
AN 1983:453635 CAPLUS
DN 99:53635
TI Double cycloaddition reaction of pyridinium N-methylides to methylenecyclopropenes leading to cage compounds
AU Tsuge, Otohiko; Kanemasa, Shuji; Takenaka, Shigeori
CS Interdisc. Grad. Sch. Eng. Sci., Kyushu Univ., Kasuga, 816, Japan
SO Chem. Lett. (1983), (4), 519-22
CODEN: CMLTAG; ISSN: 0366-7022
DT Journal
LA English
IT **86551-85-1P 86551-86-2P 86551-87-3P**
86551-88-4P 86551-89-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 86551-85-1 CAPLUS
CN 7H-3,6,6a-Metheno-3H-benzo[f]pyrrolo[3,2,1-ij]quinoline-5,5,7(6H)-tricarbonitrile, 11b,11c-dihydro-6,12-diphenyl-,

(3.alpha.,6.alpha.,6a.alpha.,7.beta.,11b.beta.,11c.beta.,12R*)- (9CI) (CA INDEX NAME)



RN 86551-86-2 CAPLUS
CN 7H-3,6,6a-Metheno-3H-benzo[f]pyrrolo[3,2,1-ij]quinoline-5,5(6H)-dicarboxylic acid, 7-cyano-11b,11c-dihydro-6,12-diphenyl-, diethyl ester, (3.alpha.,6.alpha.,6a.alpha.,7.beta.,11b.beta.,11c.beta.,12R*)- (9CI) (CA INDEX NAME)



RN 86551-87-3 CAPLUS
CN 7H-3,6,6a-Metheno-3H-benzo[f]pyrrolo[3,2,1-ij]quinoline-5-carboxylic acid, 7-cyano-5,6,11b,11c-tetrahydro-6,12-diphenyl-, methyl ester, (3.alpha.,5.alpha.,6.alpha.,6a.alpha.,7.beta.,11b.beta.,11c.beta.,12R*)- (9CI) (CA INDEX NAME)



RN 86551-88-4 CAPLUS
CN 7H-3,6,6a-Metheno-3H-benzo[f]pyrrolo[3,2,1-ij]quinoline-5-carboxylic acid, 7-cyano-5,6,11b,11c-tetrahydro-6,12-diphenyl-, ethyl ester, (3.alpha.,5.alpha.,6.alpha.,6a.alpha.,7.beta.,11b.beta.,11c.beta.,12R*)-(9CI) (CA INDEX NAME)



RN 86551-89-5 CAPLUS
CN 7H-3,6,6a-Metheno-3H-benzo[f]pyrrolo[3,2,1-ij]quinoline-7-carbonitrile, 5-benzoyl-5,6,11b,11c-tetrahydro-6,12-diphenyl-, (3.alpha.,5.alpha.,6.alpha.,6a.alpha.,7.beta.,11b.beta.,11c.beta.,12R*)-(9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB Thiazolium N-phenacylide and N-dicyanomethylide react with a methylenecyclopropane bearing an aryl group on the 4-position to give novel cage compds., 6,8-thiazapentacyclo[6.3.1.01,10.05,12.07,11]dodecenes , e.g. I. The reaction proceeds via an intramol. Diels-Alder reaction of the initially formed endo-[3 + 2]cycloadducts, followed by a hydrogen shift.

AN 1982:472266 CAPLUS

DN 97:72266

TI Formation of novel cage compounds via endo-[3 + 2] cycloadducts between thiazolium N-methylides and methylenecyclopropenes

AU Tsuge, Otohiko; Shimoharada, Hiroshi; Noguchi, Michihiko; Kanemasa, Shuji

CS Res. Inst. Ind. Sci., Kyushu Univ., Kasuga, 816, Japan

SO Chem. Lett. (1982), (5), 711-14
CODEN: CMLTAG; ISSN: 0366-7022

DT Journal

LA English

IT **82562-82-1P 82562-83-2P 82571-79-7P**
82597-72-6P 82597-73-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 82562-82-1 CAPLUS

CN 6H-2,5,5a-Metheno-2H-benzo[g]pyrrolo[1,2,3-cd]benzothiazole-6-carbonitrile, 4-benzoyl-4,5,10b,10c-tetrahydro-5,11-diphenyl-,

(2.alpha.,4.alpha.,5.alpha.,5a.alpha.,6.beta.,10b.beta.,10c.beta.,11R*)-
(9CI) (CA INDEX NAME)



RN 82562-83-2 CAPLUS
CN 6H-2,5,5a-Metheno-2H-benzo[g]pyrrolo[1,2,3-cd]benzothiazole-4,4,6(5H)-tricarbonitrile, 10b,10c-dihydro-5,11-diphenyl-, (2.alpha.,5.alpha.,5a.alpha.,6.beta.,10b.beta.,10c.beta.,11R*)- (9CI) (CA INDEX NAME)



RN 82571-79-7 CAPLUS
CN 1,10c,11-Metheno-1H,10cH-anthra[9,1-fg]pyrrolo[1,2,3-cd]benzothiazole-12,12(11H)-dicarbonitrile, 2a,13a-dihydro-6-hydroxy-11,14-diphenyl- (9CI) (CA INDEX NAME)



RN 82597-72-6 CAPLUS
CN 6H-2,5,5a-Metheno-2H-benzo[g]pyrrolo[1,2,3-cd]benzothiazole-6-carbonitrile, 4-benzoyl-4,5,10b,10c-tetrahydro-5,11-diphenyl-, (2.alpha.,4.alpha.,5.alpha.,5a.alpha.,6.alpha.,10b.beta.,10c.beta.,11R*)-(9CI) (CA INDEX NAME)



RN 82597-73-7 CAPLUS
CN 6H-2,5,5a-Metheno-2H-benzo[g]pyrrolo[1,2,3-cd]benzothiazole-4,4,6(5H)-tricarbonitrile, 10b,10c-dihydro-5,11-diphenyl-, (2.alpha.,5.alpha.,5a.alpha.,6.alpha.,10b.beta.,10c.beta.,11R*)- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB The title compds. I (R = H, alkyl, halo), useful as antifertility and analgesic agents, were prepd. Thus, 10.0 g 1-(3-phenyl-2-propenyl)-4-piperidinecarbonitrile, prepd. from isonipecotamide and ClCH2CH:CHPh, was cyclized in the presence of LiNEt2 to give 3.67 g 3-benzyl-1-azabicyclo[2.2.2]octane-4-carbonitrile, which was hydrolyzed to the carboxylic acid, whose cyclization in the presence of polyphosphoric acid at 120.degree. for 3 h gave, after treatment with HCl, I.HCl (R = H;II), which at 5 mg/kg s.c. relieved pain in 3 of 4 mice. Also, at 30.0 mg/kg s.c. II showed antifertility activity in 5 of the 8 female hamsters tested.
AN 1981:480737 CAPLUS
DN 95:80737
TI 2,4a-Ethanobenz[g]isoquinolin-5(1H)-ones and their use as anti-fertility and analgesic agents
IN Farr, Robert A.; Dolfini, Joseph E.
PA Richardson-Merrell Inc., USA
SO U.S., 6 pp.

CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4244955	A	19810113	US 1979-34357	19790430

IT **76448-01-6P 76448-02-7P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and pharmacol. activity of)
RN 76448-01-6 CAPLUS
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro- (9CI) (CA INDEX NAME)



RN 76448-02-7 CAPLUS
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I III IV

AB 3-(Phenylmethyl)-1-azabicyclo[2.2.2]octane-4-carbonitrile (I) was isolated in 56-60% yield from 1-(3-phenyl-2-propenyl)-4-piperidinecarbonitrile (II) after heating for 20 min in THF contg. one equiv of LiNEt2 and excess Et2NH1. Also isolated from the reaction mixt. were 9-15% of recovered II

and 13% of enamine III. Chem. evidence in support of the structure of quinuclidine I was obtained upon hydrolysis of the nitrile to the corresponding carboxylic acid, which cyclized in polyphosphoric acid or H2SO4/HCCl3 to give the ethanobenzisoquinolinone IV. A mechanism to account for the formation of I involving reversible formation of benzylic carbanion is proposed.

AN 1981:121283 CAPLUS
DN 94:121283
TI Intramolecular anionic cycloaddition of 1-(3-phenyl-2-propenyl)-4-piperidinecarbonitrile. Synthesis of the 2,4a-ethanobenz[g]isoquinolin-5(1H)-one ring system
AU Farr, Robert A.; Dolfini, Joseph E.; Carr, Albert A.
CS Merrell Res. Cent., Cincinnati, OH, 45215, USA
SO J. Org. Chem. (1981), 46(6), 1212-15
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
IT **76448-01-6P 76448-02-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 76448-01-6 CAPLUS
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro- (9CI) (CA INDEX NAME)



RN 76448-02-7 CAPLUS
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2002 ACS
GI



I



II



III



IV



V



VI

AB Spiro compds. (I; R = Me, PhCH2; Z = bond, O, CH2) were prepd. by a sequence of reactions involving the pinacol rearrangement of 9-(1-ethoxycarbonyl-4-piperidinyl)fluorene-9,4'-diol or the cyclization of 1-benzyl-4-(o-substituted phenyl)-4-carboxy(or cyano)piperidine. Pyridylxanthene or -anthracene derivs. II and III and phenanthro[9,10-d]azepine deriv. IV were also prepd. by the Wagner-Meerwein rearrangement of .alpha.-hydroxy spiro compds. V. Among the compds. synthesized, the spiro(azepinefluorene) deriv. VI showed marked anticonvulsant activity.

AN 1980:76260 CAPLUS

DN 92:76260

TI Studies on psychotropic agents. V. Synthesis of 1-substituted spiro[dibenz[b,f]oxepin-11,4'-piperidine]-10(11H)-one and related compounds

AU Nagai, Yasutaka; Uno, Hitoshi

CS Res. Lab., Dainippon Pharm. Co., Ltd., Suita, Japan

SO Chem. Pharm. Bull. (1979), 27(9), 2056-64
CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

IT **72643-50-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)

RN 72643-50-6 CAPLUS

CN Spiro[phenanthrene-9(10H),4'-piperidin]-10-ol, 1'-methyl- (9CI) (CA INDEX NAME)



IT **72643-59-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with Et chloroformate)
RN 72643-59-5 CAPLUS
CN Spiro[phenanthrene-9(10H),4'-piperidin]-10-one, 1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **72643-49-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. of)
RN 72643-49-3 CAPLUS
CN Spiro[phenanthrene-9(10H),4'-piperidine]-1'-carboxylic acid, 10-oxo-, ethyl ester (9CI) (CA INDEX NAME)



IT **72643-51-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 72643-51-7 CAPLUS
CN Spiro[phenanthrene-9(10H),4'-piperidin]-10-one, 1'-methyl- (9CI) (CA INDEX NAME)



=>

9980965.trn10/01/2003

=> file stnguide
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 108.83 | 289.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | -13.63 | -13.63

FILE 'STNGUIDE' ENTERED AT 17:03:03 ON 13 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 10, 2002 (20020510/UP).

=>
Connection closed by remote host

---Logging off of STN---

END

Unable to generate the STN prompt.
Exiting the script...

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

```
 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 09:59:41 ON 17 MAY 2002

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:59:56 ON 17 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   15 MAY 2002  HIGHEST RN 416838-75-0
DICTIONARY FILE UPDATES:  15 MAY 2002  HIGHEST RN 416838-75-0

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s tetralin/cn
L1            1 TETRALIN/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   119-64-2  REGISTRY
CN   Naphthalene, 1,2,3,4-tetrahydro- (8CI, 9CI)  (CA INDEX NAME)
OTHER NAMES:
```

9980965.trn10/01/2003

CN 1,2,3,4-Tetrahydronaphthalene
CN Benzocyclohexane
CN Tetrahydronaphthalene
CN **Tetralin**
CN Tetranap
FS 3D CONCORD
MF C10 H12
CI COM
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4763 REFERENCES IN FILE CA (1967 TO DATE)
246 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
4773 REFERENCES IN FILE CAPLUS (1967 TO DATE)
11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s spirotetralin
0 SPIROTETRALIN
L2 0 SPIROTETRALIN

=> s spiro-tetralin
310714 SPIRO
1 SPIROS
310714 SPIRO
(SPIRO OR SPIROS)
716 TETRALIN
L3 0 SPIRO-TETRALIN
(SPIRO(W)TETRALIN)

=> file stnguide
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 19.10 19.31

FILE 'STNGUIDE' ENTERED AT 10:02:15 ON 17 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 10, 2002 (20020510/UP).

9980965.trn10/01/2003

=>
=> logoff y
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 2.76 | 22.07

STN INTERNATIONAL LOGOFF AT 10:29:59 ON 17 MAY 2002

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:36:40 ON 17 MAY 2002

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'REGISTRY' ENTERED AT 10:39:01 ON 17 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 15 MAY 2002 HIGHEST RN 416838-75-0
DICTIONARY FILE UPDATES: 15 MAY 2002 HIGHEST RN 416838-75-0

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 9980965iso.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

L11 STRUCTURE UPLOADED

=> d l11
L11 HAS NO ANSWERS
L11 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l11
SAMPLE SEARCH INITIATED 10:51:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5858 TO ITERATE

17.1% PROCESSED 1000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 112575 TO 121745
PROJECTED ANSWERS: 29 TO 439

L12 2 SEA SSS SAM L11

=> s l11 ful
FULL SEARCH INITIATED 10:51:13 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 116632 TO ITERATE

100.0% PROCESSED 116632 ITERATIONS 343 ANSWERS
SEARCH TIME: 00.00.02

L13 343 SEA SSS FUL L11

=> file uspatall
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 140.28 548.74

FILE 'USPATFULL' ENTERED AT 10:51:20 ON 17 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:51:20 ON 17 MAY 2002

=> s l13
L14 27 L13

=> l14 and piperdi?
L14 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l14 and piperdi?
L15 2 L14 AND PIPERDI?

=> d abs bib hitstr 1-2

L15 ANSWER 1 OF 2 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:25037 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5614523 19970325
AI US 1995-470512 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180158-08-1P 180158-10-5P 180158-74-1P**
180158-75-2P
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-10-5 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-7-methoxy-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-09-2
CMF C26 H30 N2 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-74-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-yloxy)propyl]- (9CI) (CA INDEX NAME)



RN 180158-75-2 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-

yloxy)propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-74-1
CMF C25 H28 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **180160-95-6 180160-96-7**
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)

RN 180160-95-6 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 180160-96-7 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



L15 ANSWER 2 OF 2 USPATFULL

AB There are disclosed certain novel compounds identified as spiro piperidines and homologs which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such spiro compounds as the active ingredient thereof are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 96:108962 USPATFULL
TI Spiro piperidines and homologs promote release of growth hormone
IN Chen, Meng-Hsin, Westfield, NJ, United States
Johnston, David B. R., Warren, NJ, United States
Nargund, Ravi P., East Brunswick, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Tata, James R., Westfield, NJ, United States
Yang, Lihu, Edison, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5578593 19961126
AI US 1993-146848 19931103 (8)
RLI Continuation-in-part of Ser. No. US 1992-989322, filed on 11 Dec 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Covington, Raymond
LREP Thies, J. Eric, Rose, David L.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **185523-35-7P**
(prepn. of N-(.alpha.-aminoalkanoyl)spiropiperidines as growth hormone release promoters)

RN 185523-35-7 USPATFULL
CN Propanamide, 2-amino-N-[2-(3,4-dihydrospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **134697-64-6**, 3,4-Dihydrospiro[naphthalene-1(2H),4'-piperidine]
(prepn. of N-(.alpha.-aminoalkanoyl)spiropiperidines as growth hormone release promoters)
RN 134697-64-6 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro- (9CI) (CA INDEX NAME)



IT **185525-57-9P**
(prepn. of N-(.alpha.-aminoalkanoyl)spiropiperidines as growth hormone release promoters)
RN 185525-57-9 USPATFULL
CN Carbamic acid, [2-[[2-(3,4-dihydrospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s l14 and pain
L16 11 L14 AND PAIN

=> d abs bib fhitstr 1-11

L16 ANSWER 1 OF 11 USPATFULL
AB Piperidine compounds having the general formula (I), ##STR1##

wherein R.sup.1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2##

wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:44235 USPATFULL
TI Piperidine derivatives having anxiolytic effect
IN Moltzen, Ejner K., Frederiksberg C, Denmark
Perregaard, Jens Kristian, Jaegerspris, Denmark
PA H. Lundbeck A/S, Copenhagen-Valby, Denmark (non-U.S. corporation)
PI US 6207677 B1 20010327
AI US 1999-391290 19990907 (9)
RLI Continuation of Ser. No. US 1995-486510, filed on 7 Jun 1995, now patented, Pat. No. US 6031099 Division of Ser. No. US 1993-166647, filed on 13 Dec 1993, now patented, Pat. No. US 5665725 Continuation of Ser.

No. WO 1992-DK183, filed on 12 Jun 1992
PRAI DK 1991-1129 19910613
DK 1991-1131 19910613
DK 1992-157 19920210
DT Utility
FS Granted
EXNAM Primary Examiner: Huang, Evelyn Mei
LREP Darby & Darby
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2119
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **147835-16-3P**
(prepn. of, as .sigma.-receptor antagonist)
RN 147835-16-3 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

Ref. not good checked.

CM 1

CRN 147835-15-2
CMF C24 H31 N



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L16 ANSWER 2 OF 11 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:4747 USPATFULL

TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6172073 B1 20010109
AI US 1998-49837 19980327 (9)
RLI Division of Ser. No. US 1995-467434, filed on 6 Jun 1995, now patented, Pat. No. US 5741789 Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Patent
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Lentz, Nelsen L.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180158-08-1P**
(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L16 ANSWER 3 OF 11 USPATFULL
AB Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:24773 USPATFULL
TI Piperidine derivates having anxiolytic effect
IN Moltzen, Ejner K., Frederiksberg C, Denmark
Perregaard, Jens Kristian, Jaegerspris, Denmark
PA H. Lundbeck A/S, Copenhagen-Valby, Denmark (non-U.S. corporation)
PI US 6031099 20000229

AI US 1995-486510 19950607 (8)
RLI Division of Ser. No. US 166647
PRAI DK 1991-1129 19910613
DK 1991-1131 19910613
DK 1992-157 19920210
DT Utility
FS Granted
EXNAM Primary Examiner: Huang, Evelyn Mei
LREP Darby & Darby
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2042
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **147835-16-3P**
(prepn. of, as .sigma.-receptor antagonist)
RN 147835-16-3 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147835-15-2
CMF C24 H31 N



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L16 ANSWER 4 OF 11 USPATFULL
AB Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenyalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may

together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:111951 USPATFULL
TI Piperidine derivatives having anxiolytic effect
IN Moltzen, Ejner K., Frederiksberg C, Denmark
Perregaard, Jens Kristian, Jaegerspris, Denmark
PA H. Lundbeck A/S, Copenhagen-Valby, Denmark (non-U.S. corporation)
PI US 5807871 19980915
AI US 1995-478563 19950607 (8)
RLI Division of Ser. No. US 1993-166647, filed on 13 Dec 1993
PRAI DK 1991-1129 19910613
DK 1991-1131 19910613
DK 1992-157 19920210
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Dahlen, Garth M.
LREP Darby & Darby
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2055
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **147835-16-3P**
(prepn. of, as .sigma.-receptor antagonist)
RN 147835-16-3 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147835-15-2
CMF C24 H31 N



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L16 ANSWER 5 OF 11 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:92024 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5789402 19980804
AI US 1995-471121 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Berch, Mark L.; Assistant Examiner: Kifle, Bruck
LREP Palmberg, Arleen, Boone, David E.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5961
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180158-08-1P**
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L16 ANSWER 6 OF 11 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:42357 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5741789 19980421
AI US 1995-467434 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Kifle, Bruck
LREP Palmberg, Arleen, Boone, David E.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5902
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180158-08-1P**
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L16 ANSWER 7 OF 11 USPATFULL
AB Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or

S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:81274 USPATFULL
TI Piperidine derivatives having anxiolytic effect
IN Moltzen, Ejner K., Frederiksberg C, Denmark
Perregaard, Jens Kristian, Jaegerspirs, Denmark
PA Lundbeck, H., Copenhagen-Valby, Denmark (non-U.S. individual)
PI US 5665725 19970909
AI US 1993-166647 19931213 (8)
PRAI DK 1991-1129 19910613
DK 1991-1131 19910613
DK 1992-157 19920210
DT Utility
FS Granted
EXNAM Primary Examiner: Chang, Ceila
LREP Darby & Darby
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **147835-16-3P**
(prepn. of, as .sigma.-receptor antagonist)
RN 147835-16-3 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147835-15-2
CMF C24 H31 N



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L16 ANSWER 8 OF 11 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:38539 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5627196 19970506
AI US 1995-468948 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180158-08-1P**
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L16 ANSWER 9 OF 11 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:25037 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5614523 19970325
AI US 1995-470512 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180158-08-1P**
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L16 ANSWER 10 OF 11 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are

particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 96:106493 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5576321 19961119
AI US 1995-468900 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180158-08-1P**
(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L16 ANSWER 11 OF 11 USPATFULL
AB Novel spiro benzocyclane acetic acid compounds of the formula ##SPC1##

Wherein R is selected from the group consisting of hydrogen and linear and branched alkyl of one to four carbon atoms, R.sub.1 is selected from the group consisting of hydrogen, chlorine, trifluoromethyl and lower alkoxy, Y is selected from the group consisting of methylene, oxygen and sulfur, n is 2, 3 or 4 and R.sub.2 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl of one to six carbon atoms and cation of non-toxic, pharmaceutically acceptable mineral and organic bases, processes for their preparation and novel intermediates. The compounds of formula I have analgesic and anti-inflammatory properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 72:40328 USPATFULL
TI SPIRO BENZOCYCLANE ACETIC ACID COMPOUNDS
IN Rousseau, Genevieve, Paris, France
Allais, Andres, Les Lilas, France
Poittevin, Andre, Vaires-sur-Marne, France
PA Roussel Uclof, Paris, France
PI US 3682964 19720808
AI US 1970-68530 19700831 (5)
DT Utility
FS Granted

EXNAM Primary Examiner: Jiles, Henry R.; Assistant Examiner: Shurko, Cecilia M.
LREP Hammond & Littell
CLMN Number of Claims: 14
DRWN No Drawings
LN.CNT 1534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **33413-63-7P**
(prepn. of)
RN 33413-63-7 USPATFULL
CN Spiro[cyclohexane-1,1'(2'H)-naphthalene]-6'-acetic acid, 3',4'-dihydro-4'-oxo- (8CI, 9CI) (CA INDEX NAME)



=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	92.07	640.81

FILE 'CAPLUS' ENTERED AT 10:58:10 ON 17 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 May 2002 VOL 136 ISS 20
FILE LAST UPDATED: 15 May 2002 (20020515/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d his

```
     (FILE 'HOME' ENTERED AT 10:36:40 ON 17 MAY 2002)

     FILE 'REGISTRY' ENTERED AT 10:39:01 ON 17 MAY 2002
L1             STRUCTURE UPLOADED
L2          2627 S L1 FUL
L3             3 S L1
L4             STRUCTURE UPLOADED
L5             1 S L4
L6             STRUCTURE UPLOADED
L7             0 S L6
L8           255 S L6 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:42:47 ON 17 MAY 2002
L9            74 S L8
L10           19 S L9 AND ( PAIN OR ANALGESIC)

     FILE 'REGISTRY' ENTERED AT 10:50:44 ON 17 MAY 2002
L11            STRUCTURE UPLOADED
L12           2 S L11
L13         343 S L11 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 10:51:20 ON 17 MAY 2002
L14           27 S L13
L15            2 S L14 AND PIPERDI?
L16           11 S L14 AND PAIN

     FILE 'CAPLUS' ENTERED AT 10:58:10 ON 17 MAY 2002

=> s l13 and (piperid? and pain )
           104 L13
         79878 PIPERID?
         24920 PAIN
           745 PAINS
         25487 PAIN
                 (PAIN OR PAINS)
L17          1 L13 AND (PIPERID? AND PAIN )

=> d abs bib hitstr

L17  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2002 ACS
GI
```



I II

```
AB   The title compds. [I; r = 0-4; s = 0-1; D = a residue which combines with
     the carbon atoms to which it is attached to complete a pyrrolyl group; X =
     H, Ph, OH, MeO; R = (un)substituted piperazino, piperidino,
```

etc.], useful for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor, were prepd. and formulated. Thus, refluxing of (S)-(+)-4-(oxiranylmethoxy)-1H-indole with 4-amino-1-benzylpiperidine in MeOH afforded 78% (2S)-(-)-II. Compds. I are effective at 20-25 mg/day when administered to a patient in need of or carrying out a redn. or cessation of tobacco or nicotine use. Compds. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression, anxiety, hypertension, cognitive disorders, psychosis, sleep disorders, gastric motility disorders, sexual dysfunction, brain trauma, memory loss, eating disorders and obesity, substance abuse, obsessive-compulsive disorder, panic disorder, migraine, **pain**, bulimia, premenstrual syndrome, late luteal syndrome, alcoholism, dementia of aging, social phobia, attention deficit hyperactivity disorder, impulsive control disorders, chronic fatigue syndrome, premature ejaculation, anorexia nervosa, and autism.

AN 1997:260110 CAPLUS
DN 126:305591
TI Preparation of heteroaryloxy alkanamines having effects on serotonin-related systems
IN Audia, James E.; Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PA Eli Lilly and Company, USA
SO U.S., 63 pp. Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5614523	A	19970325	US 1995-470512	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
PRAI	US 1995-373823	B2	19950117		

OS MARPAT 126:305591
IT **180158-08-1P 180158-10-5P 180158-74-1P**
180158-75-2P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)
RN 180158-08-1 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-10-5 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-7-methoxy-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-09-2
CMF C26 H30 N2 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-74-1 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-yloxy)propyl]- (9CI) (CA INDEX NAME)



RN 180158-75-2 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-

yloxy)propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-74-1
CMF C25 H28 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **180160-95-6 180160-96-7**
RL: RCT (Reactant)
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)

RN 180160-95-6 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 180160-96-7 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-7-methoxy- (9CI)

(CA INDEX NAME)




```
=> s l13 and (piperid? and analges? )
          104 L13
        79878 PIPERID?
        46906 ANALGES?
L18         8 L13 AND (PIPERID? AND ANALGES? )

=> d abs bib hitstr 1-8
```

L18 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2002 ACS

AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequence of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of detg. binding of compds. to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amt. of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amt. of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

AN 2002:31619 CAPLUS

DN 136:96697

TI Human melanin concentrating hormone receptor MCH1, its DNA, its synthetic ligands and diagnostic and therapeutic uses thereof

IN Salon, John A.; Laz, Thomas M.; Nagorny, Raisa; Wilson, Amy E.

PA Synaptic Pharmaceutical Corporation, USA

SO PCT Int. Appl., 524 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002002744	A2	20020110	WO 2001-US21350	20010705

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-610635 A 20000705

IT **387825-93-6P 387825-94-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(human melanin concg. hormone receptor MCH1, its DNA, its synthetic ligands and diagnostic and therapeutic uses thereof)

RN 387825-93-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(2,1,3-benzoxadiazol-5-yl)-1-[[[3-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)propyl]amino]carbonyl]-1,2,3,6-tetrahydro-4-methyl-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 387825-94-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1-[[[3-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)propyl]amino]carbonyl]-1,2,3,6-tetrahydro-4-methyl-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



IT **387827-11-4P 387827-12-5P 387827-13-6P**
387827-14-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(human melanin concg. hormone receptor MCH1, its DNA, its synthetic ligands and diagnostic and therapeutic uses thereof)

RN 387827-11-4 CAPLUS
CN Carbamic acid, [3-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 387827-12-5 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2(1H)-one, 1'-(3-aminopropyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 387827-13-6 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(2,1,3-benzoxadiazol-5-yl)-1-[[[3-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)propyl]amino]carbonyl]-1,2,3,6-tetrahydro-4-methyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 387827-14-7 CAPLUS
CN 5-Pyrimidinecarboxylic acid, 6-(3,4-difluorophenyl)-1-[[[3-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)propyl]amino]carbonyl]-1,2,3,6-tetrahydro-4-methyl-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2002 ACS
GI



I II

AB A series of heterocyclyloxy-substituted alkanamines I [m = 0-4; n = 0-1; D = atoms to complete fused pyrrolo, imidazolo, pyrido, pyrazino, pyridazino, or pyrimido nucleus (only pyrido is claimed); X = H, Ph, OH, OMe; X = H or Ph when m = 0; R = certain (un)substituted cyclic, bicyclic, and spirocyclic amino groups] are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor (no data). Some I show a unique combination of 5-HT1A receptor activity and serotonin reuptake inhibition. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used. Over 200 synthetic examples and 7 std. formulation examples are given. In the only example of a claimed compd. (quinoline-derived, D = pyrido), reaction of (R)-5-(oxiranylmethoxy)quinoline with 6-chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole in EtOH gave the preferred compd. II in 87% yield.
AN 1998:250697 CAPLUS
DN 128:294709
TI Heterocyclyloxyalkanamines having effects on serotonin-related systems

IN Hibschman, David J.; Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.
PA Eli Lilly and Co., USA
SO U.S., 65 pp. Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5741789	A	19980421	US 1995-467434	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
	US 6172073	B1	20010109	US 1998-49837	19980327
PRAI	US 1995-373823	B2	19950117		
	US 1995-467434	A3	19950606		

OS MARPAT 128:294709
IT **180158-08-1P 180158-10-5P 180158-75-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180158-08-1 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-10-5 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-7-methoxy-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-09-2
CMF C26 H30 N2 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-75-2 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-74-1
CMF C25 H28 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **180160-95-6 180160-96-7**
RL: RCT (Reactant)
(starting material; prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180160-95-6 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 180160-96-7 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB A series of heterocyclyloxy-substituted alkanamines I [m = 0-4; n = 0-1; D = atoms to complete fused pyrrolo, imidazolo, pyrido, pyrazino, pyridazino, or pyrimido nucleus; X = H, Ph, OH, OMe; X = H or Ph when r = 0; R = (un)substituted **piperidino**, piperazino, **piperidinylamino**, piperazinoamino, morpholinoamino, certain spirocyclic amino substituents, etc.] are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor (no data). Some I show a unique combination of 5-HT1A receptor activity and serotonin reuptake inhibition. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used. Over 200 synthetic examples and 7 std. formulation examples are given. For instance, reaction of (S)-(+)-4-(oxiranylmethoxy)-1H-indole with 4-(3,4-methylenedioxyphenyl)**piperidine** gave a preferred title compd., II, isolated as the oxalate in 71% overall yield.

AN 1997:344806 CAPLUS
DN 127:34133
TI Heterocyclyloxyalkanamines having effects on serotonin-related systems
IN Audia, James E.; Hibschman, David J.; Krushinski, Joseph H. Jr.; Mabry, Thomas E.; Nissen, Jeffrey S.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PA Eli Lilly and Company, USA
SO U.S., 65 pp. Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5627196	A	19970506	US 1995-468948	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111

PRAI US 1995-373823 B2 19950117
OS MARPAT 127:34133
IT **180158-08-1P 180158-10-5P 180158-75-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180158-08-1 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-10-5 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-7-methoxy-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-09-2
CMF C26 H30 N2 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-75-2 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-74-1
CMF C25 H28 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **180160-95-6 180160-96-7**
RL: RCT (Reactant)
(starting material; prepn. of heterocyclyloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180160-95-6 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 180160-96-7 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB The title compds. [I; r = 0-4; s = 0-1; D = a residue which combines with the carbon atoms to which it is attached to complete a pyrrolyl group; X = H, Ph, OH, MeO; R = (un)substituted piperazino, **piperidino**, etc.], useful for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor, were prepd. and formulated. Thus, refluxing of (S)-(+)-4-(oxiranylmethoxy)-1H-indole with 4-amino-1-benzylpiperidine in MeOH afforded 78% (2S)-(-)-II. Compds. I are effective at 20-25 mg/day when administered to a patient in need of or carrying out a redn. or cessation of tobacco or nicotine use. Compds. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression, anxiety, hypertension, cognitive disorders, psychosis, sleep disorders, gastric motility disorders, sexual dysfunction, brain trauma, memory loss, eating disorders and obesity, substance abuse, obsessive-compulsive disorder, panic disorder, migraine, pain, bulimia, premenstrual syndrome, late luteal syndrome, alcoholism, dementia of aging, social phobia, attention deficit hyperactivity disorder, impulsive control disorders, chronic fatigue syndrome, premature ejaculation, anorexia nervosa, and autism.

AN 1997:260110 CAPLUS
DN 126:305591
TI Preparation of heteroaryloxy alkanamines having effects on serotonin-related systems
IN Audia, James E.; Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PA Eli Lilly and Company, USA
SO U.S., 63 pp. Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 5614523	A	19970325	US 1995-470512	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
PRAI	US 1995-373823	B2	19950117		

OS MARPAT 126:305591

IT **180158-08-1P 180158-10-5P 180158-74-1P**
180158-75-2P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)

RN 180158-08-1 CAPLUS

CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-10-5 CAPLUS

CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-7-methoxy-, ethanedioate (1:1) (salt)

(9CI) (CA INDEX NAME)

CM 1

CRN 180158-09-2
CMF C26 H30 N2 O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 180158-74-1 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-yloxy)propyl]- (9CI) (CA INDEX NAME)



RN 180158-75-2 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180158-74-1
CMF C25 H28 N2 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **180160-95-6 180160-96-7**
RL: RCT (Reactant)
(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)

RN 180160-95-6 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 180160-96-7 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB The title compds. I [Na = N (which may form a quaternary ammonium salt with alkyl, etc.), or N-oxide; Z = C(R8R9)Z1, etc.; Z1 = O, etc.; R = (un)substituted aryl; n = 0 - 5; p, q = 0 or 1 (a proviso is given); X1 = CO, etc. (a proviso is given); X2 = O, S, etc. (a proviso is given); R1 - R4 = H, alkyl; further details on R1 and R2 are given; R5 = H, (un)substituted alkyl, etc.; R8, R9 = H, alkyl, etc.; ring Bz = (un)substituted benzene] are claimed. In an in vitro test for NK-1 receptor antagonism, the title compd. II (prepn. given) showed IC50 of 2 nM.

AN 1995:997446 CAPLUS
DN 124:175840

TI Preparation of spiro heterocyclic compounds as tachykinin antagonists

IN Kubota, Hirokazu; Okamoto, Yoshinori; Fujii, Masahiro; Kakefuda, Akio; Yamamoto, Osamu; Nagaoka, Hitoshi; Ikeda, Ken; Isomura, Yasuo
PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9528389	A1	19951026	WO 1995-JP713	19950412
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9522234	A1	19951110	AU 1995-22234	19950412
PRAI	JP 1994-101936		19940415		
	JP 1994-255382		19941020		
	WO 1995-JP713		19950412		

OS MARPAT 124:175840

IT **173941-68-9P 173943-85-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiro heterocyclic compds. as tachykinin antagonists)

RN 173941-68-9 CAPLUS
CN Benzamide, N-[2-(3,4-dichlorophenyl)-4-(3,4-dihydro-2-hydroxyspiro[naphthalene-1(2H),4'-piperidin]-1'-yl)butyl]-N-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 173941-67-8
CMF C32 H36 Cl2 N2 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 173943-85-6 CAPLUS
CN Benzamide, N-[2-(3,4-dichlorophenyl)-4-(3,4-dihydro-2-oxospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)



L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB A series of 5 spiro compds., a new class of conformationally restricted analogs of 4-alkyl-4-(m-hydroxyphenyl)**piperidines** (I, R = H, Me, or phenethyl), were synthesized and their affinities for .mu., .delta. and .kappa. opioid receptor sites and in vivo analgetic activities detd. I show rather low affinities for the 3 receptors, with some modulation by the N-substituent and by the position of the phenolic group. To help understand the origin of this poor affinity compared to the unrestricted 4-alkyl-4-phenylpiperidines, energy conformation calcns. were performed which indicated that all the analogs favor a Ph equatorial over a Ph axial conformer. Significant differences in the lowest energy conformation were found between these spiro analogs and both morphine and 4-n-propyl-4-(m-hydroxyphenyl)**piperidines** which are conformationally unrestricted, closely related analogs with high .mu.-receptor affinity. These differences could account for their lower affinities. To continue the search for more active members of the family, structure variations which favor a phenyl-axial conformation have been identified and proposed for further study.

AN 1992:439790 CAPLUS

DN 117:39790

TI Structure-activity studies of morphine fragments. III. Synthesis, opiate receptor binding, analgetic activity and conformational studies of

spiro-[tetralin-1,4'-**piperidines**]
AU Lawson, J. A.; Toll, L.; Polgar, W.; Uyeno, E. T.; Loew, G. H.
CS SRI Int., Menlo Park, CA, 94025, USA
SO Eur. J. Med. Chem. (1991), 26(8), 775-85
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English
IT **139157-97-4 139157-98-5 139157-99-6**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(**analgesic** activity of and opiate receptor binding by, structure in relation to)
RN 139157-97-4 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-5-ol, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 139157-98-5 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-6-ol, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 139157-99-6 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-7-ol, 3,4-dihydro- (9CI) (CA INDEX NAME)



IT **139158-00-2 139158-01-3**

RL: PRP (Properties)
(conformation of, opiate receptor binding in relation to)
RN 139158-00-2 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-5-ol, 3,4-dihydro-1',2-dimethyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 139158-01-3 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-5-ol, 3,4-dihydro-1',2,2-trimethyl- (9CI) (CA INDEX NAME)



IT **139157-92-9P 139157-93-0P 139157-94-1P**
139157-95-2P 139157-96-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and **analgesic** activity and opiate receptor binding by, structure in relation to)
RN 139157-92-9 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-5-ol, 3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



HCl

RN 139157-93-0 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-6-ol, 3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 139157-94-1 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-7-ol, 3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 139157-95-2 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-5-ol, 3,4-dihydro-1'-methyl- (9CI) (CA INDEX NAME)



RN 139157-96-3 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-5-ol, 3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



IT **139157-89-4P 139157-90-7P 139157-91-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and redn. and demethylation of)
RN 139157-89-4 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2'-one, 3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)



RN 139157-90-7 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2'-one, 3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)



RN 139157-91-8 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-2'-one, 3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2002 ACS
GI



AB Aryl(pyridinyl)alkenes I (R1 = R2 = OMe, R3R4 = double bond, n = 1; R1 = R2 = H, R3R4 = double bond, n = 0) and pyridinylalkanone II (R1 = OMe, H, n = 1,2) are prepd. and converted to phenylpyridylalkanes I (R3 = R4 = H, n = 0, 1, 2 same R1, R2); their methoidides III are reduced to yield the

corresponding tetrahydropyridines, where upon cyclization by HBr or H3PO4 gave title spiro[naphthalene-1(2H),4'-**piperidines**] IV. Compds. of type IV exhibit notable activity in the writhing test, whereas the hydroxylated derivs. are definitely less active.

AN 1990:423667 CAPLUS
DN 113:23667
TI Intramolecular alkylation of aromatic compounds. XXVIII. Synthesis and pharmacological test of homologated and hydroxylated 3,4-dihydro-1'-methylspiro[naphthalene-1(2H),4'-**piperidines**]
AU Reimann, Eberhard; Speckbacher, Johann; Schuenemann, Juergen
CS Inst. Pharm. Lebensmittelchem., Univ. Muenchen, Munich, D-8000/2, Fed. Rep. Ger.
SO Arch. Pharm. (Weinheim, Ger.) (1990), 323(1), 35-9
CODEN: ARPMAS; ISSN: 0365-6233
DT Journal
LA German
OS CASREACT 113:23667
IT **113018-73-8P 113018-74-9P 127781-44-6P**
127781-45-7P 127781-46-8P 127781-47-9P
127781-48-0P 127781-83-3P 127781-84-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 113018-73-8 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-6-ol, 3,4-dihydro-1'-methyl- (9CI) (CA INDEX NAME)



RN 113018-74-9 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-6-methoxy-1'-methyl- (9CI) (CA INDEX NAME)



RN 127781-44-6 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-6,7-dimethoxy-1'-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 127781-45-7 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-6-methoxy-1'-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 127781-46-8 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-8-ol, 3,4-dihydro-1'-methyl-, hydrochloride (9CI) (CA INDEX NAME)



HCl

RN 127781-47-9 CAPLUS

CN Spiro[naphthalene-1(2H),4'-piperidin]-6-ol, 3,4-dihydro-1'-methyl-, hydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 127781-48-0 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-6-ol, 3,4-dihydro-1'-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 127781-83-3 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidin]-8-ol, 3,4-dihydro-1'-methyl- (9CI) (CA INDEX NAME)



RN 127781-84-4 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-6,7-dimethoxy-1'-methyl- (9CI) (CA INDEX NAME)



L18 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB A methadone congener I [**66194-37-4**], in which the metabolically labile C-6 dimethylamino moiety was replaced with a **piperidinospiro** deriv., was reduced and acetylated. The redn. and acetylation of I produced a marked increase in the duration of **analgesia** in rats, a trend similar to that found for methadone, but the relative potencies were not similar to those for the methadone series.

AN 1978:164217 CAPLUS

DN 88:164217

TI Synthesis and **analgesic** activity of some long-acting **piperidinospiro** derivatives of methadone

AU Frincke, James M.; Henderson, Gary L.; Janssen, Paul A. J.; Van der Eycken, Cyriel A. M.

CS Dep. Pharmacol., Univ. California, Davis, Calif., USA

SO J. Med. Chem. (1978), 21(5), 474-6
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

IT **66194-37-4**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**analgesic** activity of)

RN 66194-37-4 CAPLUS

CN 3-Hexanone, 6-(3,4-dihydrospiro[naphthalene-1(2H),4'-piperidin]-1'-yl)-4,4-diphenyl-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 66194-36-3
CMF C32 H37 N O



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **66194-34-1P 66194-35-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and **analgesic** activity of)
RN 66194-34-1 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidine]-1'-butanol, .alpha.-ethyl-3,4-dihydro-.beta.,.beta.-diphenyl- (9CI) (CA INDEX NAME)



RN 66194-35-2 CAPLUS
CN Spiro[naphthalene-1(2H),4'-piperidine]-1'-butanol, .alpha.-ethyl-3,4-dihydro-.beta.,.beta.-diphenyl-, acetate (ester) (9CI) (CA INDEX NAME)



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	47.99	688.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.58	-5.58

FILE 'STNGUIDE' ENTERED AT 11:00:56 ON 17 MAY 2002

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 10, 2002 (20020510/UP).

=>
=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.78	689.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.58

STN INTERNATIONAL LOGOFF AT 11:08:31 ON 17 MAY 2002

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Jan 25  BLAST(R) searching in REGISTRY available in STN on the Web
 NEWS  3  Jan 29  FSTA has been reloaded and moves to weekly updates
 NEWS  4  Feb 01  DKILIT now produced by FIZ Karlsruhe and has a new update
                  frequency
 NEWS  5  Feb 19  Access via Tymnet and SprintNet Eliminated Effective 3/31/02
 NEWS  6  Mar 08  Gene Names now available in BIOSIS
 NEWS  7  Mar 22  TOXLIT no longer available
 NEWS  8  Mar 22  TRCTHERMO no longer available
 NEWS  9  Mar 28  US Provisional Priorities searched with P in CA/CAplus
                  and USPATFULL
 NEWS 10  Mar 28  LIPINSKI/CALC added for property searching in REGISTRY
 NEWS 11  Apr 02  PAPERCHEM no longer available on STN.  Use PAPERCHEM2 instead.
 NEWS 12  Apr 08  "Ask CAS" for self-help around the clock
 NEWS 13  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS 14  Apr 09  ZDB will be removed from STN
 NEWS 15  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS 16  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS 17  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS 18  Apr 22  Federal Research in Progress (FEDRIP) now available

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 11:38:17 ON 17 MAY 2002

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CAPLUS' ENTERED AT 11:38:25 ON 17 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
```

FILE COVERS 1907 - 17 May 2002 VOL 136 ISS 20
FILE LAST UPDATED: 15 May 2002 (20020515/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> s review sigma 1 and( analges? or pain)
        1692634 REVIEW
          24216 REVIEWS
        1704749 REVIEW
                  (REVIEW OR REVIEWS)
         161045 SIGMA
             91 SIGMAS
         161069 SIGMA
                  (SIGMA OR SIGMAS)
        7129265 1
              0 REVIEW SIGMA 1
                  (REVIEW(W)SIGMA(W)1)
          46906 ANALGES?
          24920 PAIN
            745 PAINS
          25487 PAIN
                  (PAIN OR PAINS)
L1            0 REVIEW SIGMA 1 AND( ANALGES? OR PAIN)

=> s review sigma 1 and pain
        1692634 REVIEW
          24216 REVIEWS
        1704749 REVIEW
                  (REVIEW OR REVIEWS)
         161045 SIGMA
             91 SIGMAS
         161069 SIGMA
                  (SIGMA OR SIGMAS)
        7129265 1
              0 REVIEW SIGMA 1
                  (REVIEW(W)SIGMA(W)1)
          24920 PAIN
            745 PAINS
          25487 PAIN
                  (PAIN OR PAINS)
L2            0 REVIEW SIGMA 1 AND PAIN

=> s review sigma 1 and analgesic
        1692634 REVIEW
          24216 REVIEWS
        1704749 REVIEW
```

```
                (REVIEW OR REVIEWS)
        161045 SIGMA
            91 SIGMAS
        161069 SIGMA
                (SIGMA OR SIGMAS)
       7129265 1
             0 REVIEW SIGMA 1
                (REVIEW(W)SIGMA(W)1)
         33068 ANALGESIC
         27714 ANALGESICS
         40666 ANALGESIC
                (ANALGESIC OR ANALGESICS)
L3           0 REVIEW SIGMA 1 AND ANALGESIC

=> s review  agonist 5HT2  and (analgesics
UNMATCHED LEFT PARENTHESIS 'AND (ANALGESICS'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s review  agonist 5HT2  and (analgesics)
       1692634 REVIEW
         24216 REVIEWS
       1704749 REVIEW
                (REVIEW OR REVIEWS)
         80915 AGONIST
         59422 AGONISTS
        110112 AGONIST
                (AGONIST OR AGONISTS)
           596 5HT2
             0 REVIEW  AGONIST 5HT2
                (REVIEW(W)AGONIST(W)5HT2)
         27714 ANALGESICS
L4           0 REVIEW  AGONIST 5HT2  AND (ANALGESICS)

=> s review  agonist 5HT2  and pain
       1692634 REVIEW
         24216 REVIEWS
       1704749 REVIEW
                (REVIEW OR REVIEWS)
         80915 AGONIST
         59422 AGONISTS
        110112 AGONIST
                (AGONIST OR AGONISTS)
           596 5HT2
             0 REVIEW  AGONIST 5HT2
                (REVIEW(W)AGONIST(W)5HT2)
         24920 PAIN
           745 PAINS
         25487 PAIN
                (PAIN OR PAINS)
L5           0 REVIEW  AGONIST 5HT2  AND PAIN

=> s review serotonin and analgesic
       1692634 REVIEW
         24216 REVIEWS
       1704749 REVIEW
                (REVIEW OR REVIEWS)
         57779 SEROTONIN
            44 SEROTONINS
         57783 SEROTONIN
```

```
                (SEROTONIN OR SEROTONINS)
          1142 REVIEW SEROTONIN
                (REVIEW(W)SEROTONIN)
         33068 ANALGESIC
         27714 ANALGESICS
         40666 ANALGESIC
                (ANALGESIC OR ANALGESICS)
L6           0 REVIEW SEROTONIN AND ANALGESIC

=> s review serotonin and pain
       1692634 REVIEW
         24216 REVIEWS
       1704749 REVIEW
                (REVIEW OR REVIEWS)
         57779 SEROTONIN
            44 SEROTONINS
         57783 SEROTONIN
                (SEROTONIN OR SEROTONINS)
          1142 REVIEW SEROTONIN
                (REVIEW(W)SEROTONIN)
         24920 PAIN
           745 PAINS
         25487 PAIN
                (PAIN OR PAINS)
L7          26 REVIEW SEROTONIN AND PAIN

=> d 1-5 abs bib hitstr

L7   ANSWER 1 OF 26  CAPLUS  COPYRIGHT 2002 ACS
AB   A review. Serotonin (5-hydroxytryptamine, 5-HT) induces various effects
     in the central nervous system, cardiovascular system, and gastrointestinal
     tract. The response depends primarily on the nature of the 5-HT receptors
     involved. In the light of the current knowledge about the anatomy and
     physiol. of the serotonergic system and the distribution of the various
     5-HT receptors in the organs and tissues, the established and potential
     therapeutic applications of 5-HT receptor ligands in the treatment of
     several disorders are discussed. In particular, new selective 5-HT
     receptor ligands influencing intestinal motility and pain
     perception such as the partial 5-HT4 receptor agonist tegaserod appear
     promising for a more specific treatment of irritable bowel disease.
AN   2002:306563  CAPLUS
DN   136:304169
TI   Physiological and therapeutic relevance of serotonin and the serotonergic
     system
AU   Molderings, Gerhard J.
CS   Institut fur Pharmakologie und Toxikologie, Universitat Bonn, Germany
SO   Arzneimittel-Forschung (2002), 52(3), 145-154
     CODEN: ARZNAD; ISSN: 0004-4172
PB   Editio Cantor Verlag
DT   Journal; General Review
LA   German
RE.CNT  57    THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7   ANSWER 2 OF 26  CAPLUS  COPYRIGHT 2002 ACS
AB   A review with refs. Serotonin (5-HT), a neurotransmitter and a
     neuromodulator, plays an important role in physiol. functions and in many
     pathol. conditions. The actions of 5-HT are mediated by a variety of 5-HT
     receptors, which are distributed extensively in the central nervous system
     and certain peripheral tissues. A class of drugs which specifically
```

antagonizes the 5-HT type 3 receptor (5-HT3) now occupy an important place in the therapy of cancer, since these drugs allow the use of high-dose cytotoxic treatment by blocking the nausea and vomiting triggered by cancer chemotherapeutic agents and/or radiotherapy. They are also useful as prophylactic agents in preventing postoperative nausea and vomiting due to the anesthetics used in surgical procedures. The 5-HT3 receptor antagonists (with or without other antiemetic drugs) have become the agents of choice in controlling emesis because of higher efficacy and relatively lower adverse effect profile as compared to the conventional antiemetic agents. The major site of action of these drugs appears to be the central 5-HT3 receptors, although inhibition of peripheral receptors may also play a role in the control of vomiting. The clin. efficacy as antiemetic agents and the safety profile of the various agents in this class is similar. These drugs may also be useful in the treatment of **pain**, pruritus, fibromyalgia, gastrointestinal symptoms, anxiety disorders and alc. dependency, but not enough clin. data are available to confirm their role in these disorders. The individual 5-HT3 receptor antagonists differ in pharmacokinetic properties and potential for drug-drug interaction.

AN 2001:591039 CAPLUS
DN 135:326872
TI Clinical pharmacology of serotonin receptor type 3 (5-HT3) antagonists
AU Israili, Zafar H.
CS Department of Medicine, Emory University School of Medicine, Atlanta, GA, 30303, USA
SO Current Medicinal Chemistry: Central Nervous System Agents (2001), 1(2), 171-199
CODEN: CMCCCO; ISSN: 1568-0150
PB Bentham Science Publishers Ltd.
DT Journal; General Review
LA English
RE.CNT 359 THERE ARE 359 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review, with 48 refs. Irritable bowel syndrome (IBS) is a debilitating disease, which is characterized by recurrent abdominal cramping and **pain**, and is assocd. with either constipation and/or diarrhea. It is approx. twice as prevalent in women as it is in men and is among the most common gastrointestinal (GI) disorders encountered in primary care. The etiol. of the disease is poorly understood but may include motility dysregulation, visceral sensitivity, inflammation, bacterial infection, dietary antigens, psychol. stress, GI surgery or a gut-brain phenomenon. At present, there is no acceptable treatment for IBS, although recent advances indicate that some relief may be achieved by the administration of compds. that act on 5-HT (serotonin) receptors. This suggestion is the result of numerous studies which have shown that 5-HT may exert a no. of diverse effects on human GI tissues. In addn., it has emerged that the levels of the 5-HT metabolite (5-HIAA) are raised in the plasma of IBS patients and that administration of 5-HT-like compds. may mimic the symptoms of IBS. It has therefore been proposed that therapy with compds. that act at 5-HT receptors will return the intestine to normal activity and alleviate the **pain** experienced by these patients. One compd. (alosetron, a 5-HT3 receptor antagonist) has already been released onto the market but showed benefit in female patients only and only in those whose primary symptom was diarrhea. In addn., the compd. was recently withdrawn following concerns over its safety. The reasons why alosetron only appears to show efficacy in females, why these treatments are only effective in a subset of the population of IBS patients and why alosetron elicits its particular side effect profile have not been

elucidated. One further serotonergic compd., tegaserod (Zelmac, a 5-HT4 receptor agonist), has shown promise for the treatment of patients with constipation-predominant IBS and is currently in pre-registration for this indication. It is clear, however, that further research will have to take place before the utility of serotonergic modulation in the treatment of IBS can be fully validated.

AN 2001:320874 CAPLUS
DN 135:220450
TI Serotonergic modulation and irritable bowel syndrome
AU Borman, Richard
CS Pharmagene Plc, Herts, SG8 5HD, UK
SO Emerging Drugs (2001), 6(1), 57-68
CODEN: EMDRFV; ISSN: 1361-9195
PB Ashley Publications Ltd.
DT Journal; General Review
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 138 refs. Although the past few years have seen an exponential growth of compds. of potential interest for the treatment of functional gastrointestinal (GI) tract disorders, the gap that still exists between basic and clin. research is easily noticed if one considers the relative paucity of drugs that have received marketing authorization for the treatment of irritable bowel syndrome (IBS). Traditional efficacy outcomes in drug development for IBS include the ability of the compd. to affect GI tract motility (i.e. to exert a prokinetic or an antispasmodic effect), which is thought to be of importance if a motor disorder is the underlying pathophysiol. mechanism. More recently, altered visceral sensitivity to a distending stimulus has been suggested to be a key pathophysiol. feature, at least in some patients, and has become a target for therapeutic interventions. However, there is now growing consensus that the primary outcome measure in the treatment of functional disorders are those that reflect overall control of the patient's symptoms (**pain**, diarrhea, constipation) in everyday situations such as the clin. global improvement scales. Although, in general, guidelines on the design of treatment trials for functional GI tract disorders advise against subcategorization of patients according to the main symptom (because of symptom instability), subcategorization indeed makes sense esp. in IBS (constipation- or diarrhea-predominant). Compds. with a specific indication for each subpopulation of patients are now emerging. The rationale for investigations on serotonin (5-hydroxytryptamine; 5-HT) receptor ligands in IBS rests mainly on the fact that serotonin, which may be released by enterochromaffin-like cells in the GI tract as well as from other sources, has a no. of well documented motor effects on the GI tract and can produce hyperalgesia in several exptl. models. Serotonin receptors belonging to the 5-HT3 and 5-HT4 subtype are the most extensively studied in gastroenterol., although hitherto 'orphan' receptor subtypes, such as the 5-HT7 and the 5-HT1B/D receptors, are now emerging. Among 5-HT3 receptor antagonists, alosetron was recently approved for the treatment of diarrhea-predominant IBS and is an example of a compd. that, at least theor., may act at multiple levels: by inhibiting visceral sensitivity, by increasing compliance, and by inhibiting excitatory 5-HT3 receptors located on both ascending and descending neuronal pathways involved in peristalsis. For this reason, 5-HT3 receptor antagonists may slow transit, hence the specific indication of alosetron in diarrhea-predominant IBS. However, alosetron has been recently withdrawn by the manufacturer because of safety concerns. Hypomotility remains an attractive therapeutic target in IBS and the new generation of prokinetics

includes several partial agonists at the 5-HT4 receptor, such as tegaserod (HTF-919) and prucalopride (R0-93877). In addn., preliminary evidence suggests that 5-HT4 receptors may also be involved in the modulation of visceral sensitivity. Second-generation 5-HT4 receptor agonists seem to be devoid of the QT-prolonging effects obsd. in some clin. circumstances with cisapride and may be more active at the colonic level. Piboserod (SB-207266A) is a 5-HT4 receptor antagonist under development for the treatment of diarrhea-predominant IBS. Finally, interest in 5-HT7 and 5-HT1B/D receptor subtypes stems from the observation that the former receptors mediate smooth muscle relaxation (at least in the human colon), whereas sumatriptan (a 5-HT1B/D receptor agonist) can affect GI tract motility and visceral sensitivity.

AN 2001:286903 CAPLUS
DN 135:204690
TI Irritable bowel syndrome: New agents targeting serotonin receptor subtypes
AU De Ponti, Fabrizio; Tonini, Marcello
CS Department of Pharmacology, University of Bologna, Bologna, Italy
SO Drugs (2001), 61(3), 317-332
CODEN: DRUGAY; ISSN: 0012-6667
PB Adis International Ltd.
DT Journal; General Review
LA English
RE.CNT 138 THERE ARE 138 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 12 refs., on serotonin receptor subtypes; peripheral tissue serotonin in **pain** transmission and regulation; and serotonin in calcitonin-mediated analgesia.
AN 2001:102018 CAPLUS
DN 134:305352
TI The roles of 5-HT and its receptors in the **pain** transmission system
AU Senba, Emiko
CS 2nd Anatomy Class, Wakayama Medical College, Japan
SO Igaku no Ayumi (2000), 195(9), 605-608
CODEN: IGAYAY; ISSN: 0039-2359
PB Ishiyaku Shuppan
DT Journal; General Review
LA Japanese

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	57.37	57.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.10	-3.10

FILE 'STNGUIDE' ENTERED AT 11:41:18 ON 17 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 10, 2002 (20020510/UP).

=> d 6-15 abs bib hitstr

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L7 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review, with 66 refs. The study of the mechanisms of action of the triptan group of drugs has largely contributed to the progress made in the understanding of the physiopathol. processes that are possibly responsible for migraine. In this context, two discoveries have been esp. important: 1) these anti-migraine drugs are specifically recognized by three main types of serotonin receptors (5-HT1B, 5-HT1D, and 5-HT1F); and 2) these receptors are present in the meninges, where they are expressed by both smooth muscle cells and/or endothelial cells of the vascular wall and/or the perivascular trigeminal to be deleted axon terminals. These two findings have led to the most currently accepted physiopathogenic hypothesis, whereby the migraine attack would start with an excitation of the perivascular trigeminal to be deleted fibers, which would then trigger the release of vasoactive peptides (substance P, calcitonin gene-related peptide/CGRP) within the dura mater. Locally, i.e., in the dura mater in particular, these substances can provoke vasodilatation (CGRP) and plasmatic extravasation (substance P) with platelet lysis and mast cell degranulation, thereby leading to the release of algogenic substances that excite the neighboring trigeminal fibers, and this neurogenic inflammatory response can progressively extend to the meninges as a whole. This reaction subsequently reaches the bulbar and thalamic nuclei and then the sensory cortex, where it is integrated and expressed as migraine **pain**. The aim of this article was to report the main findings on endogenous substances (serotonin, peptides, nitric oxide [NO], etc.) which appear to play a key role in this physiopathogenic sequence.
AN 2000:841515 CAPLUS
DN 134:250277
TI The role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine: current hypotheses
AU Hamon, M.; Bourgoin, S.
CS Inserm U288, faculte de medecine Pitie-Salpetriere, Paris, 75634, Fr.
SO Pathologie Biologie (2000), 48(7), 619-629
CODEN: PTBIAN; ISSN: 0031-3009
PB Editions Scientifiques et Medicales Elsevier
DT Journal; General Review
LA French
RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 17 refs. on endogenous descending inhibitory/facilitatory system and serotonin (5-HT) modulating spinal nociceptive transmission with subdivision headings: (1) descending inhibitory/facilitatory system in brain stem and (2) modulation of spinal nociceptive transmission by 5-HT.
AN 2000:602254 CAPLUS
DN 134:250169
TI Endogenous descending inhibitory/facilitatory system and serotonin (5-HT) modulating spinal nociceptive transmission
AU Zhang, Yuqiu; Wu, Gencheng
CS State Key Laboratory of Medical Neurobiology, Shanghai Medical University, Shanghai, 200032, Peop. Rep. China
SO Shengli Kexue Jinzhan (2000), 31(3), 211-216
CODEN: SLKHA8; ISSN: 0559-7765
PB Zhongguo Shengli Xuehui
DT Journal; General Review

LA Chinese

L7 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review, with 104 refs., on available information regarding the functional and therapeutic implications of 5-HT receptor diversity, >15 have been identified by mol. cloning, for neurol. and psychiatry. 5-HT receptors are divided into seven main families: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. Several families (e.g., 5-HT1 family) have many members (e.g., 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), each of which is encoded by a distinct gene product. In addn. to the genomic diversity of 5-HT receptors, splice variants and editing isoforms exist for many of the 5-HT receptors, making the family even more diverse. Evidence that is summarized in this review suggests that 5-HT receptors represent novel therapeutic targets for a no. of neurol. and psychiatric diseases including migraine headaches, chronic **pain** conditions, schizophrenia, anxiety, depression, eating disorders, obsessive compulsive disorder, pervasive developmental disorders, and obesity-related conditions (type II diabetes, hypertension, obesity syndromes). It is possible that subtype-selective serotonergic agents may revolutionize the treatment for a no. of medical, psychiatric, and neurol. disorders.
AN 2000:588201 CAPLUS
DN 133:291186
TI The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches?
AU Roth, Bryan L.; Lopez, Estelle; Patel, Shamil; Kroeze, Wesley K.
CS Department of Psychiatry, Department of Biochemistry, Department of Neuroscience, Case Western Reserve University Medical School, Cleveland, OH, 44106-4935, USA
SO Neuroscientist (2000), 6(4), 252-262
CODEN: NROSFJ; ISSN: 1073-8584
PB Sage Publications, Inc.
DT Journal; General Review
LA English
RE.CNT 104 THERE ARE 104 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 26 refs. Brain serotonergic neurons display a distinctive slow and regular discharge pattern in behaving animals. This activity gradually declines across the arousal-waking sleep cycle, becoming virtually silent during rapid eye movement sleep. The activity of these neurons, in both the pontine and medullary groups, is generally unresponsive to a variety of physiol. challenges or stressors. However, these neurons are activated in assocn. with increased muscle tone/tonic motor activity, esp. if the motor activity is in the repetitive or central pattern generator mode. The authors interpret these data within the following theor. framework. The primary function of the brain serotonergic system is to facilitate motor output. Concurrently, the system coordinates autonomic and neuroendocrine function with the present motor demand, and inhibits information processing in various sensory pathways. Reciprocally, when the serotonin system is briefly inactivated (e.g., during orientation to salient stimuli), this disfacilitates motor function and disinhibits sensory information processing. It is within this context that serotonin exerts its well-known effects on **pain**, feeding, memory, mood, etc.
AN 1999:507458 CAPLUS
DN 131:307170
TI Activity of serotonergic neurons in behaving animals
AU Jacobs, Barry L.; Fornal, Casimir A.
CS Program in Neuroscience, Department of Psychology, Princeton University,

Princeton, NJ, 08544, USA
SO Neuropsychopharmacology (1999), 21(2S), 9S-15S
CODEN: NEROEW; ISSN: 0893-133X
PB Elsevier Science Inc.
DT Journal; General Review
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 135 refs. The development and clin. use of the serotonin 5-HT1 receptor agonists, collectively known as the "triptans", has ushered in a new age for clinicians treating patients with migraine, as well as a new era for those who respond to the medicines. The triptans that are currently in use (sumatriptan, naratriptan, rizatriptan and zolmitriptan) and those in development [almotriptan, eletriptan and frovatriptan (SB-209509, VML-251)] all share a common pharmacol. of 5-HT1B/1D receptor agonist activity. Administration of a triptan during an acute migraine is aimed, via an interruption of the pathophysiol. of this disorder, at rapid and well tolerated relief of headache and assocd. symptoms of migraine. Migraine probably involves a combination of cranial vasodilatation, with peripheral trigeminal nerve activation and consequent excitation of trigeminal neurons within the caudal brainstem and upper cervical spinal cord (the trigeminocervical complex). Triptans may act by constricting cranial vessels through 5-HT1B receptors, by inhibiting peripheral trigeminal nerve afferents that innervate the vessels and **pain** -producing dura mater through 5-HT1D receptors, or by inhibiting central trigeminal neuronal traffic through 5-HT1D receptors, or by a combination of these mechanisms. Peripheral neuronal inhibition is likely to involve inhibition of calcitonin gene-related peptide (CGRP) release and perhaps to some degree inhibition of a trigeminally driven inflammatory process. Some aspects of the pharmacokinetics of the various triptans, such as the relationship between time to reach peak plasma concns. and half-lives and clin. efficacy, may reveal information about the fundamental processes at work in acute migraine. The triptans have been a source of considerable interest because they have provided important clues to the basic pathophysiol. of migraine and point to an important role for the CNS in this disorder.
AN 1998:749148 CAPLUS
DN 130:162588
TI Serotonin 5-HT1B/1D receptor agonists in migraine: comparative pharmacology and its therapeutic implications
AU Goadsby, Peter J.
CS Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
SO CNS Drugs (1998), 10(4), 271-286
CODEN: CNDREF; ISSN: 1172-7047
PB Adis International Ltd.
DT Journal; General Review
LA English
RE.CNT 135 THERE ARE 135 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 232 refs. Serotonin (5-hydroxytryptamine) is an important biogenic amine that fulfills the role of neurotransmitter and neuromodulator. It has been a focus of interest during the last decade. Its diversity of pharmacol. actions is related to a wide variety of receptors and effector mechanisms. Seven serotonin receptor families have been identified thus far. They are genetically different transmembrane

proteins composed of several hundred amino acids. The majority of these are G-protein-coupled, except the 5-HT3 receptors, which are directly ligand gated to fast ion channels. Serotonin is widely distributed in the body within the central and peripheral nervous systems, smooth muscles, and platelets, in particular. Consequently, its effects manifest mainly in these organs and influence a wide variety of neural, vascular, smooth muscle, and platelet functions. (Melatonin, a physiol. active metabolite of serotonin, is also instrumental in affecting many neural and hormonal functions.). Several selective agonists and particularly many selective antagonists have been developed for serotonin, which helped the serotonin receptor subtype classification. Some of these drugs are also used therapeutically in the treatment of migraine (eg, sumatriptan, which is a 5-HT1 receptor agonist), vascular disorders (5-HT2 antagonists), and nausea and vomiting (5-HT3 antagonists, eg, dolasetron, granisetron, ondansetron, and tropisetron), and have been investigated in gastrointestinal motility disorders (5-HT4 antagonists) and behavioral psychopathologies (5-HT1 agonists and 5-HT2-4 antagonists). Serotonin reuptake inhibitors are of particular clin. importance in the treatment of psychol. illnesses. Future use of these drugs is also envisioned in the treatment of certain types of **pain** syndromes. Awareness of the serotonergic drugs and the recognition of possible drug interactions among drugs that influence serotonergic mechanisms in humans are becoming increasingly important in the practice of anesthesiol.

AN 1997:365215 CAPLUS
DN 127:28509
TI Pharmacology of serotonin as related to anesthesia
AU Gyermek, Laszlo
CS Department of Anesthesiology, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance, CA, USA
SO J. Clin. Anesth. (1996), 8(5), 402-425
CODEN: JCLBE7; ISSN: 0952-8180
PB Elsevier
DT Journal; General Review
LA English

L7 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review and discussion, with 52 refs., of serotonin receptors in relation to migraine therapy which discusses: the peripheral pathways including trigeminal innervation of **pain**-sensitive intracranial structures, plasma protein extravasation and migraine in relation to a model of peripheral drug action; and the central nervous system including exptl. cerebral blood flow studies, selective stimulation of **pain** -sensitive structures, and clin. observations of the trigeminovascular system.

AN 1996:700546 CAPLUS
DN 125:317521
TI Central and peripheral 5-hydroxytryptamine receptor effects: What have we learnt?
AU Goadsby, Peter J.
CS Institute Neurology, London, WC1N 3BG, UK
SO Migraine: Pharmacol. Genet. (1996), 67-81. Editor(s): Sandler, Merton; Ferrari, Michel; Harnett, Sara. Publisher: Chapman & Hall, London, UK.
CODEN: 63NSAC
DT Conference; General Review
LA English

L7 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 108 refs. Antagonists of the serotonin 5-HT3 receptor are clin. effective antinausea and anti-emetic drugs for the treatment of cancer patients undergoing chemotherapy and for patients undergoing

procedures involving general anesthesia. These compds. have also been evaluated for the treatment of irritable bowel syndrome, other **pain**-related disorders (including migraine) and a variety of central nervous system disorders (including anxiety, psychosis and the treatment of drug abuse). The status of research into potential clin. applications of these drugs is evaluated in this review. The evidence from preclin. and clin. studies is compared and avenues for future drug development using these compds. are discussed.

AN 1996:306379 CAPLUS
DN 125:89
TI 5-HT3 receptor antagonists
AU Silverstone, P. H.; Greenshaw, A. J.
CS Clinical Psychopharmacology Res. Unit, Univ. Alberta, Alberta, T6G 2B7, Can.
SO Expert Opin. Ther. Pat. (1996), 6(5), 471-481
CODEN: EOTPEG; ISSN: 1354-3776
DT Journal; General Review
LA English

L7 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review with 112 refs. There are conflicting results on the function of 5-HT in anxiety and depression. To reconcile this evidence, Deakin and Graeff have suggested that the ascending 5-HT pathway that originates in the dorsal raphe nucleus (DNR) and innervates the amygdala and frontal cortex facilitates conditioned fear, while the DRN-periventricular pathway innervating the periventricular and periaqueductal gray matter inhibits inborn fight/flight reactions to impending danger, **pain**, or asphyxia. To study the role of the DRN 5-HT system in anxiety, the authors microinjected 8-OH-DPAT into the DRN to inhibit 5-HT release. This treatment impaired inhibitory avoidance (conditioned fear) without affecting one-way escape (unconditioned fear) in the elevated T-maze, a new animal model of anxiety. The authors also applied 3 drug treatments that increase 5-HT release from DRN terminals: (1) intra-DRN microinjection of the benzodiazepine inverse agonist FG 4172, (2) intra-DRN microinjection of the excitatory amino acid kainic acid, and (3) i.p. injection of the 5-HT releaser and uptake blocker D-fenfluramine. All treatments enhanced inhibitory avoidance in the T-maze. D-Fenfluramine and intra-DRN kainate also decreased one-way escape. In healthy volunteers, D-fenfluramine and the 5-HT agonist mCPP (mainly 5-HT2C) increased, while the antagonists ritanserin (5-HT2A/2C) and SR 46349B (5-HT2A) decreased skin conductance responses to an aversively conditioned stimulus (tone). In addn., D-fenfluramine decreased, whereas ritanserin increased subjective anxiety induced by simulated public speaking, thought to represent unconditioned anxiety. Overall, these results are compatible with the above hypothesis. Deakin and Graeff have suggested that the pathway connecting the median raphe nucleus (MRN) to the dorsal hippocampus promotes resistance to chronic, unavoidable stress. In the present study, the authors found that 24 h after electrolytic lesion of the rat MRN glandular gastric ulcers occurred, and the immune response to the mitogen Con A was depressed. Seven days after the same lesion, the ulcerogenic effect of restraint was enhanced. Microinjection of 8-OH-DPAT, the nonselective agonist 5-MeO-DMT, or the 5-HT uptake inhibitor zimelidine into the dorsal hippocampus immediately after 2 h of restraint reversed the deficits of open arm exploration in the elevated plus-maze, measured 24 h after restraint. The effect of the two last drugs was antagonized by WAY-100135, a selective 5-HT1A receptor antagonist. These results are compatible with the hypothesis that the MRN-dorsal hippocampus 5-HT system attenuates stress by facilitation of hippocampal 5-HT1A-mediated neurotransmission. Clin. implications of these results are discussed, esp. with regard to panic disorder and

depression.
AN 1996:247120 CAPLUS
DN 124:285572
TI Role of 5-HT in stress, anxiety, and depression
AU Graeff, Frederico G.; Guimaraes, Francisco S.; De Andrade, Telma G. C. S.; Deakin, John F. W.
CS Laboratorio de Psicofoarmacologia, Universidade de Sao Paulo, Sao Paulo, 14040-901, Brazil
SO Pharmacol., Biochem. Behav. (1996), 54(1), 129-41
CODEN: PBBHAU; ISSN: 0091-3057
DT Journal; General Review
LA English

L7 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2002 ACS
AB A review, with 79 refs. Serotonin has both pro- and antinociceptive actions due to its multiple receptor types and their location (periphery, spinal cord, or brain). E.g., the S1A receptors of the periphery and spinal cord increase nociception; the S1B/1D receptors of the periphery and spinal cord decrease nociception; the S2A receptors of the periphery increase and of the brain decrease nociception; and the S3 receptors of the periphery increase and those of the spinal cord decrease nociception.
AN 1996:84257 CAPLUS
DN 124:165322
TI Serotonin (5-HT) and **pain**: a reappraisal of its role in the light of receptor multiplicity
AU Millan, Mark J.
CS Institut de Recherches Servier, Centre de Recherches de Croissy, Croissy-sur-Seine, 78290, Fr.
SO Semin. Neurosci. (1995), 7(6), 409-19
CODEN: SNEUEZ; ISSN: 1044-5765
DT Journal; General Review
LA English

=> log off y
STN INTERNATIONAL LOGOFF AT 11:57:19 ON 17 MAY 2002

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.76	0.97

FILE 'STNGUIDE' ENTERED AT 14:08:37 ON 13 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 10, 2002 (20020510/UP).

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	1.39

FILE 'REGISTRY' ENTERED AT 14:13:06 ON 13 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 12 MAY 2002 HIGHEST RN 414856-11-4
DICTIONARY FILE UPDATES: 12 MAY 2002 HIGHEST RN 414856-11-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 9980965.str

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

```
=>  sl3
SL3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
=>

=>

=>

=>

=>

=>

=>

YOU HAVE RECEIVED  8 CONSECUTIVE ARROW PROMPTS (=>)
The arrow (=>) is the system prompt, where you enter a command.  For
an explanation of system commands, files, formats, etc., enter "HELP"
and the name of the item you want explained at an arrow prompt (=>).
Enter "HELP COMMANDS" for a list of commands that can be used in this
file.  Enter "HELP MESSAGES" for a list of online explanations that
are available.  The "?" can be used as a synonym for "HELP".

Help is also available at any prompt, and after any error message.
Enter "HELP" or "?" at a prompt to see an explanation of the options.
After an error message, enter "HELP" or "?" at the next prompt and you
will receive a more detailed explanation of the error and how to
correct it.

Automatic help is also available.  When AUHELP is 'ON', you will
automatically receive help following an error message.  For more
information on AUHELP, enter "HELP SET AUHELP" at an arrow
prompt (=>).

Users who need additional assistance can contact the Help Desk at
their nearest STN Service Center.  Enter "HELP STN" for information on
STN Service Centers.  You may also choose to contact the database
representative for the file you are searching, for more detailed help
on database content and search strategy.  For information on how to
contact database representatives for the current file, enter "HELP
DESK" at an arrow prompt (=>).
IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
=>

=>

=>

=> s l3
SAMPLE SEARCH INITIATED 14:13:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   3170 TO ITERATE

 31.5% PROCESSED    1000 ITERATIONS                          2 ANSWERS
```

```
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        60025 TO    66775
PROJECTED ANSWERS:               2 TO      277

L4            2 SEA SSS SAM L3

=> s l3 ful
FULL SEARCH INITIATED 14:20:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  63701 TO ITERATE

100.0% PROCESSED   63701 ITERATIONS                          290 ANSWERS
SEARCH TIME: 00.00.02

L5          290 SEA SSS FUL L3

=> file uspatall
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   144.84     146.23

FILE 'USPATFULL' ENTERED AT 14:21:02 ON 13 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:21:02 ON 13 MAY 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l5
L6          11 L5

=> d abs bib hitstr3-6
'HITSTR3-6' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS -------- AB
ALL -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU
ALLG ------- ALL plus PAGE.DRAW
BIB -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
             PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ------- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE".  BROWSE must
             entered on the same line as DISPLAY, e.g., D BROWSE.
CAS -------- OS, CC, SX, ST, IT
CBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ------- ALL, delimited for post-processing
FP --------- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
             PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,
             NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,
             CLMN, DRWN, AB
```

```
FP.EX ------ FP for original and latest publication
FPALL ------ PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI,
             RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,
             NCLS, EXF, REP, REN,ARTU, EXNAM, LREP, CLMN, DRWN, AB,
             PARN, SUMM, DRWD, DETD, CLM
FPBIB ------ PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,
             RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN
FHITSTR ---- HIT RN, its text modification, its CA index name, and
             its structure diagram
FPG -------- FP plus PAGE.DRAW
GI --------- PN and page image numbers
HIT -------- All fields containing hit terms
HITRN ------ HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
             its structure diagram
IABS ------- ABS, indented with text labels
IALL ------- ALL, indented with text labels
IALLG ------ IALL plus PAGE.DRAW
IBIB ------- BIB, indented with text labels
IBIB.EX ---- IBIB for original and latest publication
IBIBG ------ IBIB plus PAGE.DRAW
IMAX ------- MAX, indented with text labels
IMAX.EX ---- IMAX for original and latest publication
IND -------- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU, OS, CC, SX, ST, IT
ISTD ------- STD, indented with text labels
KWIC ------- All hit terms plus 20 words on either side
MAX -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
             RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
             DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
             INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,
             EXF, ARTU OS, CC, SX, ST, IT
MAX.EX ----- MAX for original and latest publication
OCC -------- List of display fields containing hit terms
SBIB ------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT
SCAN ------- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display
             without answer number.  SCAN must be entered on the
             same line as DISPLAY, e.g., D SCAN)
STD -------- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,
             DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,
             IC, ICM, ICS, EXF (STD is the default)
STD.EX ----- STD for original and latest publication
TRIAL ------ AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,
             ICM, ICS

ENTER DISPLAY FORMAT (STD):end

=> d abs bib hitstr 3-6

L6   ANSWER 3 OF 11  USPATFULL
AB     The present invention is directed spiro-substituted azacycles of formula
       I: (wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, k, l and m are
       defined herein) which are useful as modulators of chemokine receptor
       activity. In particular, these compounds are useful as modulators of the
       chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5,
       CXCR-3, and/or CXCR-4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2000:4806  USPATFULL
```

TI Spiro-substituted azacycles as modulators of chemokine receptor activity
IN Mills, Sander G., Scotch Plains, NJ, United States
Maccoss, Malcolm, Freehold, NJ, United States
Springer, Martin S., Westfield, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 6013644 20000111
AI US 1997-989940 19971212 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Krass, Frederick
LREP Thies, J. Eric, Rose, David L.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **209280-16-0P**
(prepn. of spiro-substituted azacycles as modulators of chemokine receptor activity)
RN 209280-16-0 USPATFULL
CN Benzenesulfonamide, N-[(2S)-2-(3-chlorophenyl)-4-(1,3-dihydro-6-methoxy-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **253783-77-6**
(prepn. of spiro-substituted azacycles as modulators of chemokine receptor activity)
RN 253783-77-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 4 OF 11 USPATFULL
AB A water soluble derivative of buckministerfullerene (C.sub.60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 1998:115775 USPATFULL
TI Water soluble fullerenes with antiviral activity
IN Friedman, Simon H., San Francisco, CA, United States
Schinazi, Raymond F., Decatur, GA, United States
Wudl, Fred, Santa Barbara, CA, United States
Hill, Craig L., Atlanta, GA, United States
De Camp, Diane L., Atlanta, GA, United States
Sijbesma, Rintje P., Eindhoven, Netherlands
Kenyon, George L., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5811460 19980922
AI US 1849220 19940124 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Peters, Verny, Jones, Biksa, L.L.P.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **168770-20-5P**
(prepn. of water-sol. fullerenes with HIV antiviral activity)
RN 168770-20-5 USPATFULL
CN Dispiro[piperidine-4,3''-[3'H,3''H]dicyclopropa[1,9:52,60][5,6]fullerene-C60-Ih-3''',4''''-piperidine], conjugate diacid (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





●2 H^+

L6 ANSWER 5 OF 11 USPATFULL

AB This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:61669 USPATFULL
TI Alpha IC adrenergic receptor antagonists
IN Huff, Joel R., Gwynedd Valley, PA, United States
Lee, Hee-Yoon, Yusung-Gu, Korea, Republic of
Nerenberg, Jennie B., Maple Glen, PA, United States
Thompson, Wayne J., Lansdale, PA, United States
Bell, Ian M., Harleysville, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5760054 19980602
WO 9528397 19951026
AI US 1996-722001 19961001 (8)
WO 1995-US4590 19950413
19961001 PCT 371 date
19961001 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-229276, filed on 13 Apr 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Rotman, Alan L.
LREP Winokur, Melvin
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4070
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **173842-21-2P 173842-22-3P 173842-33-6P**
173842-34-7P 173842-35-8P 173842-36-9P
173842-37-0P 173842-38-1P 173842-39-2P

173842-40-5P 173842-41-6P 173842-42-7P
173842-43-8P 173842-44-9P 173842-46-1P
173842-47-2P 173842-79-0P 173842-86-9P
173842-87-0P 173842-89-2P
(prepn. of benzisothiazolones and analogs as .alpha.1C-adrenergic antagonists)

RN 173842-21-2 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-22-3 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[4-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 173842-33-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(3,3-dioxido-1-oxonaphth[1,2-d]isothiazol-2(1H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-34-7 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(4-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-35-8 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(7-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-36-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(5-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-37-0 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(6-methoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-38-1 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(5-methyl-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-39-2 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(5-chloro-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-40-5 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(5-fluoro-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-41-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(5-nitro-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-42-7 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(6-nitro-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-43-8 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(1,1-dioxido-3-oxoisothiazolo[5,4-c]pyridin-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-44-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(1,1-dioxido-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-46-1 USPATFULL

CN 5H-Pyrrolo[3,4-b]pyridine-5,7(6H)-dione, 6-[4-(1,3-dihydro-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-47-2 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(1,1-dioxido-3-oxonaphtho[1,8-de]-1,2-thiazin-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-79-0 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(2,3-dihydro-7,7-dioxido-9-oxo-1,4-dioxino[2,3-e][1,2]benzisothiazol-8(9H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-86-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(5-ethoxy-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-87-0 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-(5-ethyl-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)butyl]- (9CI) (CA INDEX NAME)



RN 173842-89-2 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[4-[5-(1-methylethyl)-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl]butyl]- (9CI) (CA INDEX NAME)



IT **136080-34-7**
(prepn. of benzisothiazolones and analogs as .alpha.1C-adrenergic antagonists)
RN 136080-34-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



IT **136080-24-5P 136080-25-6P**
(prepn. of benzisothiazolones and analogs as .alpha.1C-adrenergic antagonists)
RN 136080-24-5 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-benzoyl- (9CI) (CA INDEX NAME)



RN 136080-25-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one (9CI) (CA INDEX NAME)



L6 ANSWER 6 OF 11 USPATFULL
AB Spirocycles of general structural formula: ##STR1## are Class III antiarrhythmic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:45012 USPATFULL
TI Nitrogen-containing spirocycles
IN Baldwin, John J., Gwyned Valley, PA, United States
Claremon, David A., Audubon, PA, United States
Elliott, Jason M., Blue Bell, PA, United States
Ponticello, Gerald S., Lansdale, PA, United States
Remy, David C., North Wales, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5633247 19970527
AI US 1995-498525 19950705 (8)
RLI Continuation of Ser. No. US 1992-998321, filed on 30 Dec 1992, now abandoned which is a division of Ser. No. US 1991-709686, filed on 3 Jun 1991, now patented, Pat. No. US 5206240 which is a continuation-in-part of Ser. No. US 1990-612091, filed on 16 Nov 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-447950, filed on 8 Dec 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Covington, Raymond
LREP Bigley, Frank P., Daniel, Mark R.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 8569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **136081-76-0P**
(prepn. of, as antiarrhythmic and cardiotonic)
RN 136081-76-0 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **136074-68-5P 136074-69-6P 136074-70-9P**
136074-71-0P 136074-72-1P 136074-73-2P
136074-74-3P 136074-75-4P 136074-76-5P
136074-77-6P 136074-78-7P 136074-79-8P
136074-80-1P 136074-81-2P
(prepn. of, as class III antiarrhythmic and cardiotonic)
RN 136074-68-5 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-69-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1-ol, 1,3-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-70-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[2-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-71-0 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1-ol, 1,3-dihydro-1'-[2-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-72-1 USPATFULL
CN Methanesulfonamide, N-[4-[2-(1,3-dihydro-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 136074-73-2 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 6-nitro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-74-3 USPATFULL
CN Methanesulfonamide, N-[1,3-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[2H-indene-2,4'-piperidin]-6-yl]- (9CI) (CA INDEX NAME)



RN 136074-75-4 USPATFULL
CN Methanesulfonamide, N-[1,3-dihydro-1-hydroxy-1'-[2-(2-pyridinyl)ethyl]spiro[2H-indene-2,4'-piperidin]-6-yl]- (9CI) (CA INDEX NAME)



RN 136074-76-5 USPATFULL
CN Methanesulfonamide, N-[4-[2-[1,3-dihydro-6-[(methylsulfonyl)amino]-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 136074-77-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-78-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-79-8 USPATFULL
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]- (9CI) (CA INDEX NAME)



RN 136074-80-1 USPATFULL
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 136074-81-2 USPATFULL
CN Methanesulfonamide, N-[4-[2-[3,4-dihydro-7-[(methylsulfonyl)amino]-1-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



IT **136081-75-9P**
(prepn. of, as intermediate for antiarrhythmic and cardiotonic)
RN 136081-75-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl- (9CI) (CA INDEX NAME)



IT **136080-24-5P 136080-25-6P 136080-26-7P**
136080-27-8P 136080-28-9P 136080-29-0P
136080-30-3P 136080-31-4P 136080-32-5P
136080-33-6P 136080-34-7P 136080-35-8P
136080-36-9P 136112-40-8P
(prepn. of, as intermediates for antiarrhythmic and cardiotonic)

RN 136080-24-5 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-benzoyl- (9CI) (CA INDEX NAME)



RN 136080-25-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one (9CI) (CA INDEX NAME)



RN 136080-26-7 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl-6-nitro- (9CI) (CA INDEX NAME)



RN 136080-27-8 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 6-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 136080-28-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl-6-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 136080-29-0 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl-6-amino- (9CI) (CA INDEX NAME)



RN 136080-30-3 USPATFULL
CN Methanesulfonamide, N-(1,3-dihydro-3-oxospiro[2H-indene-2,4'-piperidin]-5-yl)- (9CI) (CA INDEX NAME)



RN 136080-31-4 USPATFULL
CN Methanesulfonamide, N-[1,3-dihydro-1'-[2-(4-nitrophenyl)ethyl]-3-oxospiro[2H-indene-2,4'-piperidin]-5-yl]- (9CI) (CA INDEX NAME)



RN 136080-32-5 USPATFULL
CN Methanesulfonamide, N-[1'-[2-(4-aminophenyl)ethyl]-1,3-dihydro-3-oxospiro[2H-indene-2,4'-piperidin]-5-yl]- (9CI) (CA INDEX NAME)



RN 136080-33-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid, 3,4-dihydro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 136080-34-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 136080-35-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 136080-36-9 USPATFULL
CN Methanesulfonamide, N-(3,4-dihydro-1-oxospiro[naphthalene-2(1H),4'-piperidin]-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 136112-40-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME)



=> d abs bib hitstr 1-2

L6 ANSWER 1 OF 11 USPATFULL
AB A water soluble derivative of buckministerfullerene (C.sub.60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:206004 USPATFULL
TI Water soluble fullerenes with antiviral activity
IN Friedman, Simon H., San Francisco, CA, United States
Schinazi, Raymond F., Decatur, GA, United States
Wudl, Fred, Santa Barbara, CA, United States
Hill, Craig L., Atlanta, GA, United States
DeCamp, Diane L., Atlanta, GA, United States
Sijbesma, Rintje P., Eindhoven, Netherlands

Kenyon, George L., San Francisco, CA, United States
PA The Regents of the University of California (U.S. corporation)
PI US 2001041801 A1 20011115
AI US 2001-771082 A1 20010125 (9)
RLI Division of Ser. No. US 1998-246011, filed on 21 Sep 1998, GRANTED, Pat. No. US 6204391 Continuation of Ser. No. US 1994-184922, filed on 24 Jan 1994, GRANTED, Pat. No. US 5811460
DT Utility
FS APPLICATION
LREP HOWARD M. PETERS, PETERS, VERNY, JONES & BIKSA, LLP, Suite 6, 385 Sherman Avenue, Palo Alto, CA, 94306
CLMN Number of Claims: 43
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **168770-20-5P**
(prepn. of water-sol. fullerenes with HIV antiviral activity)
RN 168770-20-5 USPATFULL
CN Dispiro[piperidine-4,3''-[3'H,3''H]dicyclopropa[1,9:52,60][5,6]fullerene-C60-Ih-3''',4''''-piperidine], conjugate diacid (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



●2 H^+

L6 ANSWER 2 OF 11 USPATFULL

AB A water soluble derivative of buckministerfullerene (C.sub.60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:40605 USPATFULL

TI Water soluble fullerenes with antiviral activity

IN Friedman, Simon H., San Francisco, CA, United States
Schinazi, Raymond F., Decatur, GA, United States
Wudl, Fred, Santa Barbara, CA, United States
Hill, Craig L., Atlanta, GA, United States

DeCamp, Diane L., Atlanta, GA, United States
Sijbesma, Rintje P., Eindhoven, Netherlands
Kenyon, George L., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6204391 B1 20010320
AI US 1998-246011 19980921 (9)
RLI Continuation of Ser. No. US 1994-184922, filed on 24 Jan 1994, now patented, Pat. No. US 5811460
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Peters, Verny Jones & Biksa, LLP
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 16 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **168770-20-5P**
(prepn. of water-sol. fullerenes with HIV antiviral activity)
RN 168770-20-5 USPATFULL
CN Dispiro[piperidine-4,3''-[3'H,3''H]dicyclopropa[1,9:52,60][5,6]fullerene-C60-Ih-3''',4''''-piperidine], conjugate diacid (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



●2 H^+

=>

=> d abs bib hitstr 7-11

L6 ANSWER 7 OF 11 USPATFULL

AB There are disclosed certain novel compounds identified as spiro piperidines and homologs which promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone.

Growth hormone releasing compositions containing such spiro compounds as the active ingredient thereof are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 96:108962 USPATFULL
TI Spiro piperidines and homologs promote release of growth hormone
IN Chen, Meng-Hsin, Westfield, NJ, United States
Johnston, David B. R., Warren, NJ, United States
Nargund, Ravi P., East Brunswick, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Tata, James R., Westfield, NJ, United States
Yang, Lihu, Edison, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5578593 19961126
AI US 1993-146848 19931103 (8)
RLI Continuation-in-part of Ser. No. US 1992-989322, filed on 11 Dec 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Covington, Raymond
LREP Thies, J. Eric, Rose, David L.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **185523-29-9P 185523-30-2P 185523-31-3P**
(prepn. of N-(.alpha.-aminoalkanoyl)spiropiperidines as growth hormone release promoters)
RN 185523-29-9 USPATFULL
CN Propanamide, 2-amino-N-[2-(1,3-dihydro-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 185523-30-2 USPATFULL
CN Propanamide, 2-amino-N-[2-(1,3-dihydro-1-hydroxyspiro[2H-indene-2,4'-

piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl-, [1'(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185523-31-3 USPATFULL
CN Propanamide, 2-amino-N-[2-(1,3-dihydrospiro[2H-indene-2,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **185525-48-8P 185525-49-9P 185525-50-2P 185525-51-3P 185525-52-4P 185525-53-5P**
(prepn. of N-(.alpha.-aminoalkanoyl)spiropiperidines as growth hormone release promoters)
RN 185525-48-8 USPATFULL
CN Propanamide, 2-amino-N-[2-(1,3-dihydro-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185525-49-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185525-50-2 USPATFULL
CN Carbamic acid, [2-[[2-(1,3-dihydro-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185525-51-3 USPATFULL
CN Spiro[2H-indene-2,4'-piperidine]-1'-carboxylic acid, 1,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 185525-52-4 USPATFULL
CN Spiro[2H-indene-2,4'-piperidine], 1,3-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185525-53-5 USPATFULL
CN Carbamic acid, [2-[[2-(1,3-dihydrospiro[2H-indene-2,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 11 USPATFULL
AB Compounds of the general structural formula: ##STR1## or a pharmaceutically acceptable salt, hydrate or crystal form thereof, wherein;

X is O or CH.sub.2

R.sup.1 is H if R.sup.2 is not H or if R.sup.2 is H then R.sup.1 is ##STR2## R.sup.2 is --H if R.sup.1 is not H or if R.sup.1 is H then R.sup.2 is; ##STR3## and R.sup.3 is ##STR4## are Class HI antiarrhythmic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:71364 USPATFULL
TI Spirocycles
IN Claremon, David A., Maple Glen, PA, United States
Ponticello, Gerald S., Lansdale, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5439914 19950808
AI US 1994-198940 19940218 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Berch, Mark L.
LREP Bigley, Francis P., Daniel, Mark R., DiPrima, Joseph F.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 736
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **171797-76-5P 171797-77-6P 171797-78-7P**
171797-79-8P
(intermediate; prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-76-5 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-4(3H)-one, 1'-benzoyl-6-methoxy- (9CI) (CA INDEX NAME)



RN 171797-77-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-4(3H)-one, 6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-78-7 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-6-methoxy-4-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-79-8 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-6-methoxy-4-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]- (9CI) (CA INDEX NAME)



IT **171797-63-0P**
(prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-63-0 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-4-hydroxy-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]- (9CI) (CA INDEX NAME)



IT **171797-64-1P 171797-65-2P 171797-66-3P**
171797-67-4P 171797-68-5P
(prepn. of spirocycles as Class III antiarrhythmic agents)
RN 171797-64-1 USPATFULL
CN Benzonitrile, 4-[2-(3,4-dihydro-4-hydroxy-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-1'-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-65-2 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]- (9CI) (CA INDEX NAME)



RN 171797-66-3 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171797-67-4 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171797-68-5 USPATFULL
CN Acetamide, N-[1'-[2-(4-cyanophenyl)ethyl]-3,4-dihydro-6-methoxyspiro[naphthalene-2(1H),4'-piperidin]-4-yl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 9 OF 11 USPATFULL

AB Compounds of formula (I): ##STR1## in which: R.sub.1 and R.sub.2, which may be identical or different, represent a linear or branched (C.sub.1 C.sub.6) alkyl radical, a substituted or unsubstituted phenyl radical, a pyridyl radical or a thienyl radical, or, with the carbon atom to which they are attached, a substituted or unsubstituted (C.sub.4 -C.sub.7) cycloalkyl ring,

R.sub.3 represents

a substituted or unsubstituted phenylsulfonyl radical,

a linear or branched (C.sub.1 -C.sub.6) alkyl radical,

an alkylaminocarbonyl radical,

or a linear or branched (C.sub.1 -C.sub.6) acyl radical,

R.sub.4 represents any one of the radicals:

--CH.dbd.CH--(CH.sub.2).sub.p --CO.sub.2 H or --CH.sub.2 --CH.sub.2 --(CH.sub.2)p--CO.sub.2 H

in which p is equal to 0, 1, 2 or 3, n and m, which may be identical or different, represent 0, 1 or 2,

their isomers, enantiomers, diastereoisomers and epimers as well as their addition salts with a pharmaceutically acceptable acid or base.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 95:67331 USPATFULL
TI Alkenecarboxylic acid compounds
IN Lavielle, Gilbert, La Celle Saint Cloud, France
Hautefaye, Patrick, Servon Brie Comte Robert, France
Laubie, Michel, Vaucresson, France
Verbeuren, Tony, Vernouillet, France
PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)
PI US 5436343 19950725
AI US 1993-62080 19930514 (8)
PRAI FR 1992-5905 19920515
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Jones, Dwayne C.
LREP Hueschen, Gordon W.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **154678-95-2P**
(prepn. and reaction of, in prepn. of aminoalkenecarboxylic acid thromboxane A2 receptor antagonist)
RN 154678-95-2 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidine]-3',5'-dicarbonitrile, 3,4-dihydro-2',6'-dioxo-, ammonium salt (9CI) (CA INDEX NAME)



● NH_3

L6 ANSWER 10 OF 11 USPATFULL
AB Spirocycles of general structural formula: ##STR1## are Class III antiarrhythmic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 93:33493 USPATFULL
TI Nitrogen-containing spirocycles
IN Baldwin, John J., Gwynedd Valley, PA, United States
Elliott, Jason M., Blue Bell, PA, United States
Claremon, David A., Audubon, PA, United States
Ponticello, Gerald S., Lansdale, PA, United States
Remy, David C., North Wales, PA, United States
Selnick, Harold G., Ambler, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206240 19930427
AI US 1991-709686 19910603 (7)
RLI Continuation-in-part of Ser. No. US 1990-612091, filed on 16 Nov 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-447950, filed on 8 Dec 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Brust, Joseph P.; Assistant Examiner: Haley, Jacqueline
LREP Daniel, Mark R., DiPrima, Joseph F.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **136081-76-0P**
(prepn. of, as antiarrhythmic and cardiotonic)
RN 136081-76-0 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **136074-68-5P 136074-69-6P 136074-70-9P**
136074-71-0P 136074-72-1P 136074-73-2P
136074-74-3P 136074-75-4P 136074-76-5P
136074-77-6P 136074-78-7P 136074-79-8P
136074-80-1P 136074-81-2P
(prepn. of, as class III antiarrhythmic and cardiotonic)
RN 136074-68-5 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-69-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1-ol, 1,3-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-70-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-[2-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-71-0 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1-ol, 1,3-dihydro-1'-[2-(4-

nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-72-1 USPATFULL
CN Methanesulfonamide, N-[4-[2-(1,3-dihydro-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 136074-73-2 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 6-nitro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-74-3 USPATFULL
CN Methanesulfonamide, N-[1,3-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[2H-indene-2,4'-piperidin]-6-yl]- (9CI) (CA INDEX NAME)



RN 136074-75-4 USPATFULL
CN Methanesulfonamide, N-[1,3-dihydro-1-hydroxy-1'-[2-(2-pyridinyl)ethyl]spiro[2H-indene-2,4'-piperidin]-6-yl]- (9CI) (CA INDEX NAME)



RN 136074-76-5 USPATFULL
CN Methanesulfonamide, N-[4-[2-[1,3-dihydro-6-[(methylsulfonyl)amino]-1-oxospiro[2H-indene-2,4'-piperidin]-1'-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 136074-77-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-78-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 3,4-dihydro-1'-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 136074-79-8 USPATFULL
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]- (9CI) (CA INDEX NAME)



RN 136074-80-1 USPATFULL
CN Methanesulfonamide, N-[3,4-dihydro-1-oxo-1'-[2-(2-pyridinyl)ethyl]spiro[naphthalene-2(1H),4'-piperidin]-7-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 136074-81-2 USPATFULL
CN Methanesulfonamide, N-[4-[2-[3,4-dihydro-7-[(methylsulfonyl)amino]-1-oxospiro[naphthalene-2(1H),4'-piperidin]-1'-yl]ethyl]phenyl]- (9CI) (CA INDEX NAME)



IT **136081-75-9P**
(prepn. of, as intermediate for antiarrhythmic and cardiotonic)
RN 136081-75-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl- (9CI) (CA INDEX NAME)



IT **136080-24-5P 136080-25-6P 136080-26-7P**

136080-27-8P 136080-28-9P 136080-29-0P
136080-30-3P 136080-31-4P 136080-32-5P
136080-33-6P 136080-34-7P 136080-35-8P
136080-36-9P 136112-40-8P
(prepn. of, as intermediates for antiarrhythmic and cardiotonic)

RN 136080-24-5 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-benzoyl- (9CI) (CA INDEX NAME)



RN 136080-25-6 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one (9CI) (CA INDEX NAME)



RN 136080-26-7 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl-6-nitro- (9CI) (CA INDEX NAME)



RN 136080-27-8 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 6-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 136080-28-9 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl-6-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 136080-29-0 USPATFULL
CN Spiro[2H-indene-2,4'-piperidin]-1(3H)-one, 1'-acetyl-6-amino- (9CI) (CA INDEX NAME)



RN 136080-30-3 USPATFULL
CN Methanesulfonamide, N-(1,3-dihydro-3-oxospiro[2H-indene-2,4'-piperidin]-5-yl)- (9CI) (CA INDEX NAME)



RN 136080-31-4 USPATFULL
CN Methanesulfonamide, N-[1,3-dihydro-1'-[2-(4-nitrophenyl)ethyl]-3-oxospiro[2H-indene-2,4'-piperidin]-5-yl]- (9CI) (CA INDEX NAME)



RN 136080-32-5 USPATFULL
CN Methanesulfonamide, N-[1'-[2-(4-aminophenyl)ethyl]-1,3-dihydro-3-oxospiro[2H-indene-2,4'-piperidin]-5-yl]- (9CI) (CA INDEX NAME)



RN 136080-33-6 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid, 3,4-dihydro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 136080-34-7 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 136080-35-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 136080-36-9 USPATFULL
CN Methanesulfonamide, N-(3,4-dihydro-1-oxospiro[naphthalene-2(1H),4'-piperidin]-7-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 136112-40-8 USPATFULL
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-acetyl-3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 11 USPATFULL
AB 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one derivatives are described which are useful as analgesic and anti-fertility agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 81:2388 USPATFULL
TI 2,4a-Ethanobenz[g]isoquinolin-5(1H)-ones and their use as anti-fertility and analgesic agents
IN Farr, Robert A., Cincinnati, OH, United States
Dolfini, Joseph E., Cincinnati, OH, United States
PA Richardson-Merrell Inc., Wilton, CT, United States (U.S. corporation)
PI US 4244955 19810113
AI US 1979-34357 19790430 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Daus, Donald G.; Assistant Examiner: Springer, D. B.
LREP Stein, William J., Conte, Salvatore R.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1,4,5

DRWN No Drawings
LN.CNT 467
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **76448-01-6P 76448-02-7P**
(prepn. and pharmacol. activity of)
RN 76448-01-6 USPATFULL
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro- (9CI) (CA INDEX NAME)



RN 76448-02-7 USPATFULL
CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	76.50	222.73

FILE 'CAPLUS' ENTERED AT 14:25:57 ON 13 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 May 2002 VOL 136 ISS 20
FILE LAST UPDATED: 10 May 2002 (20020510/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> d his

     (FILE 'HOME' ENTERED AT 14:07:27 ON 13 MAY 2002)

     FILE 'REGISTRY' ENTERED AT 14:07:38 ON 13 MAY 2002
L1             STRUCTURE UPLOADED
L2          22 S L1

     FILE 'STNGUIDE' ENTERED AT 14:08:37 ON 13 MAY 2002

     FILE 'REGISTRY' ENTERED AT 14:13:06 ON 13 MAY 2002
L3             STRUCTURE UPLOADED
L4           2 S L3
L5         290 S L3 FUL

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:21:02 ON 13 MAY 2002
L6          11 S L5

     FILE 'CAPLUS' ENTERED AT 14:25:57 ON 13 MAY 2002

=> s l5
L7          41 L5

=> file stnguide
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.40     223.13

FILE 'STNGUIDE' ENTERED AT 14:26:38 ON 13 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 10, 2002 (20020510/UP).

=>

---Logging off of STN---


Connection closed by remote host
END

 Unable to generate the STN prompt.
 Exiting the script...


Welcome to STN International!  Enter x:x
```